# EDGAR Filing Document

**Accession Number:** 0001799207
**File Stem:** 0000950103-26-003540
**Filing Date:** 2026-3
**Character Count:** 167022
**Document Hash:** 859423f44892346e829b62851cde3229
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950103-26-003540.hdr.sgml**: 20260310

**ACCESSION NUMBER**: 0000950103-26-003540

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260310

**FILED AS OF DATE**: 20260310

**DATE AS OF CHANGE**: 20260310

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AUNA S.A.
- **CENTRAL INDEX KEY:** 0001799207
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41982
- **FILM NUMBER:** 26739532

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 6, RUE JEAN MONNET
- **CITY:** GRAND DUCHY OF LUXEMBOURG
- **PROVINCE COUNTRY:** N4
- **ZIP:** L-2180
- **BUSINESS PHONE:** 51 (205-3500)

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 6, RUE JEAN MONNET
- **CITY:** GRAND DUCHY OF LUXEMBOURG
- **PROVINCE COUNTRY:** N4
- **ZIP:** L-2180

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AUNA S.A.A.
- **DATE OF NAME CHANGE:** 20200930

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AUNA S.A.
- **DATE OF NAME CHANGE:** 20200108

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of March 2026

**Commission File Number: 001**-**41982**

**Auna S.A.**

**(Exact name of registrant as specified in its charter)**

**‎ 6, rue Jean Monnet**

**L-2180 Luxembourg**

**Grand Duchy of Luxembourg**

**‎+51 1-205-3500‎**

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F X Form 40-F  

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| **EXHIBIT** |  |
| [99.1](dp243087_ex9901.htm) | [Press release dated March 10, 2026 — Auna announces 4Q25 and FY25 Financial Results](dp243087_ex9901.htm) |
| [99.2](dp243087_ex9902.htm) | [Consolidated Financial Statements as of and for the year ended December 31, 2025](dp243087_ex9902.htm) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| **Auna S.A.** | **Auna S.A.** | **Auna S.A.** |
| By: | /s/ Gisele Remy | /s/ Gisele Remy |
|  | Name: | Gisele Remy |
|  | Title: | Chief Financial Officer |

---

Date: March 10, 2026

## Exhibit 99.1

**EXHIBIT 99.1**

**Auna Announces 4Q25 and FY25 Financial Results**

**Auna Closes FY 2025 with Strong Performance in Peru and Colombia** 

**and 35% increase in Free Cash Flow** 

**Signs of Recovery in Mexico in 2026**

**Company Sets 12% Adjusted EBITDA Growth Guidance for 2026**

**Luxembourg, March 10, 2026 – Auna (NYSE: AUNA) ("Auna" or the "Company")**, a leading healthcare platform in Latin America with operations in Mexico, Peru, and Colombia, announced today financial results for the fourth quarter ended December 31, 2025 ("fourth quarter 2025" or "4Q25") and full-year ended 2025 ("full-year 2025" or "FY25"). Financial results are expressed in Peruvian Soles ("S/" or "PEN") and are presented in accordance with International Financial Reporting Standards ("IFRS"), unless otherwise noted.

FY25 Consolidated Highlights

● Revenue increased 4% FXN to S/4,385 million, and was flat on reported basis

● Adjusted EBITDA decreased 3% FXN, or 8% YoY on reported basis, to S/917 million

● Adjusted EBITDA Margin of 20.9%, down 1.7 p.p. YoY from 22.6% in FY24

● Operating Cash Flow and Free Cash Flow increased 2% YoY and 35% YoY, respectively

● Adjusted Net Income was S/336 million, up from S/146 million in FY24

● Oncology MLR decreased to record 48.5% since 2022, down from 53.0% in FY24

4Q25 Consolidated Highlights

● Revenue increased 6% FXN, or 7% YoY on reported basis, to S/1,133 million

● Adjusted EBITDA was S/220 million, a decrease of 14% FXN, or 13% YoY

● Adjusted EBITDA Margin of 19.5%, down 4.5 p.p. YoY from 23.9% in 4Q24

● Adjusted Net Income of S/136 million, up from S/36 million in 4Q24

● Leverage Ratio remained unchanged at 3.6x

Message from Auna's Executive Chairman and President

Auna closed fiscal year 2025 with resilient performance. Peru and Colombia delivered in line with our expectations, while consolidated performance reflected challenges in Mexico. Results in the fourth quarter of 2025 and the first two months of 2026 indicate a clear stabilization and recovery of the Mexico operations, which are now on track to

deliver sustained top-line and EBITDA growth in 2026. Under the leadership of our new management team in Mexico, we have focused on expanding our reach into the larger segments of privately insured families and further strengthening our alignment with physician groups. While these initiatives were implemented late in the year and did not offset the volume losses experienced earlier in 2025, they have strengthened the foundation of the Mexico platform and position the business to return to sustainable organic growth in 2026.

In Peru, where our integrated healthcare model continues to perform at scale, we delivered solid and predictable results. The consolidated integrated network and the healthcare delivery network increased revenues by 11% and Adjusted EBITDA by 14%. In oncology, the MLR improved to a record low of 48.5%, reflecting disciplined pricing execution and continued efficiency in care management. Peru's growth profile has been strengthened with the authorization to commence the refurbishment, completion and opening of Centro Ambulatorio Trecca in Lima in 2028, an ambulatory facility that we expect will expand our addressable market and transform how we will serve up to 3 million EsSalud beneficiaries annually.

In Mexico, where we are focused on recapturing and accelerating our growth and profitability initiatives, 4Q25 and the first two months of 2026 showed strong signs of recovery. Our decision to adjust the leadership team in Monterrey, bringing deep local expertise and execution capabilities, is already delivering early results in 2026. During the quarter, we secured favorable tier classifications with two of the market's leading insurance providers, and we confirmed other tier classifications that we believe will result in growing volumes across key service lines. We were also awarded an extension of an improved healthcare plan for ISSSTELEON employees, which we formalized earlier this year. Additionally, other initiatives to grow and diversify revenues with attractive margins, continue to gain traction. We want to highlight that better-than-expected performance from our oncology business, growing 35% from 3Q25 to reach 9% of our revenues, validates the strength of the integrated AunaWay model in Mexico.

In Colombia, results were in line with our expectations. The operation continues to demonstrate resilience as we prioritize cash generation and disciplined risk management over volume growth. We expanded our risk-sharing models from 17% of segment revenue in 4Q24 to 21% in 4Q25, and Auna now covers approximately 3 million protected lives nationwide. This deliberate migration toward more intimate solutions for payors, physicians and patients, grant us a unique opportunity to further embed Auna into many lives in Colombia. It also enables us to harvest predictable reimbursement structures, reduce business volatility, enhanced cash flow visibility, and advance our franchise in Colombia, while providing a model that can be tested in Mexico.

As we continued to scale, and notwithstanding some setbacks in Mexico, we maintained strict cost and expense management across Auna, driving a 35% increase in free cash flow versus 2024. This improvement reflects both operational stabilization, enhanced working capital management, and disciplined capital allocation. In parallel, we

successfully completed the US$825 million refinancing that has reduced interest expenses, extended our maturity profile, lowered short-term debt exposure, and increased the proportion of direct local currency funding. Taken together, these improvements have strengthened Auna's capital structure. As a result, we entered 2026 with enhanced liquidity, greater financial flexibility, and reduced cash flow volatility. Net leverage remained stable at 3.6x Net Debt-to-Adjusted EBITDA, demonstrating our ability to effectively manage the balance sheet, even during a period of operational stress. We remain committed to reducing leverage below 3x over the medium term, principally through EBITDA recovery, margin expansion, and sustained free cash flow generation.

During the second half of the year, our shares experienced sudden and relevant selling pressure primarily related to a significant shareholder that had accumulated a large holding that required the consent of Mexico's antitrust regulator. Based on certain SEC filings and to the best of our knowledge, we believe this selling pressure has finally abated, eliminating the related price overhang. While trading volume increased during the quarter, we remain committed to deepening our engagement with the investment community, expanding research coverage, and enhancing market access so that our trading profile and valuation more fully reflect the strength, scale and cash-generating capacity of Auna's integrated healthcare platform.

We saw 2025 as a year of stabilization, with an overhaul in Mexico and a strengthened capital structure. We envision 2026 to mark a return to growth, with a regional platform now more than ready to perform at high levels. Given the improved perspective and predictability across our operations, we are providing full-year revenue and Adjusted EBITDA guidance to assist investors and analysts in tracking our performance. We expect 2026 revenue and Adjusted EBITDA growth of 12% FXN, within a range of 10% to 14%. The midpoint reflects our current performance outlook, while the range accounts for any unforeseen variability.

We continue to be highly motivated to deliver regionally through our unique AunaWay model, and we expect our financial performance in 2026 and the coming years to significantly benefit all our stakeholders.

2026 Financial Guidance

For Fiscal Year 2026, Auna expects revenue growth of approximately 12% FXN, within a range of 10% to 14%, driven by continued commercial momentum and operating execution across its core markets. In addition, Auna projects Adjusted EBITDA growth of approximately 12% FXN, within a range of 10% to 14%, supported by disciplined cost management and continued reinvestment in growth initiatives that are expected to result in broadly stable margins year-over-year. As in previous years, the Company expects capital expenditures to remain at approximately 4% of revenues, consistent with its balanced approach to growth investments and cash flow generation.

Auna's guidance is based on management's current performance outlook and expected macroeconomic and regulatory conditions in the three countries where the Company operates. Any changes in these conditions could have an impact on the guidance provided.

**Disclaimer**: The 2026 financial guidance reflects management's current assumptions regarding numerous evolving factors that are difficult to accurately predict, including those discussed in the Risk Factors set forth in the Company's Form 20F filed with the United States Securities and Exchange Commission (the "SEC"). Reconciliations of forward-looking non-IFRS measures, specifically the 2026 Adjusted EBITDA guidance, to the relevant forward-looking IFRS measures are not being provided, as the Company does not currently have sufficient data to accurately estimate the variables and individual adjustments for such guidance and reconciliations. Due to this uncertainty, the Company cannot reconcile projected Adjusted EBITDA to projected net income without unreasonable effort. The 2026 financial guidance constitutes forward-looking statements. For more information, see the "Forward-Looking Statements" section in this release.

Overview of 4Q25 and Full-Year 2025 Consolidated Results

**Revenues** in 4Q25 increased 6% FXN and increased 7% YoY on a reported basis to S/1,133 million, with revenues in local currency ("LC") increasing 11% in Peru and 7% in Colombia, partially offset by a 3% decrease in Mexico. FY25 revenues increased 4% FXN and remained flat on a reported basis at S/4,385 million, with annual LC revenues increasing 9% in Peru and 5% in Colombia, partially offset by a 4% decline in Mexico. Healthcare network revenue in Mexico decreased due to softer demand for services, the slower than expected recovery from physician and supplier relationships, and despite strong oncology revenues. In Peru, Oncosalud contributed higher revenues with increases in average tickets and healthcare plan memberships, while the healthcare network experienced increased demand for services at higher price points. In Colombia, revenue growth was driven by an increase in risk-sharing models, greater diversification away from intervened payors, improving collections, and higher surgery and emergency services tickets.

**Adjusted EBITDA** in 4Q25 decreased 14% FXN, or 13% YoY on a reported basis, to S/220 million, with an Adjusted EBITDA Margin of 19.5%. Adjusted EBITDA increased 14% in Peru in LC, while declining 25% in Colombia and 36% in Mexico. Adjusted EBITDA in FY25 decreased 3% FXN, or 8% YoY on reported basis, to S/917 million, with an Adjusted EBITDA Margin of 20.9%. Annual Adjusted EBITDA increased 14% in Peru in LC, offset by decreases of 4% in Colombia and 18% in Mexico. In Mexico, Adjusted EBITDA decreased and lagged volume recoveries during the year and the impact of the ISSTELEON healthcare plan. Peru's Adjusted EBITDA increased on higher demand and tickets for hospital network services, as well as higher tickets for memberships. Colombia's Adjusted EBITDA declined due to extraordinary revenues and rebates recognized in the 4Q24 period versus 4Q25.

Our reported results were impacted by foreign exchange fluctuations, specifically, a 1% depreciation of the MXN and a 3% appreciation of the COP against the PEN.

**Net finance costs** were S/238 million in 4Q25 compared to S/155 million in 4Q24. Excluding net finance costs from exchange rate differences, as well as extraordinary refinancing costs of S/170 million incurred in 4Q25, net finance costs would have been S/116 million in 4Q25 and S/126 million in 4Q24, representing a YoY decrease of S/10 million, or 8.4%. The net finance costs from exchange rate differences in 4Q25 included a positive non-cash amount of S/48 million, compared to a negative S/24 million in 4Q24. In FY25, net finance costs were S/436 million compared to S/609 million in FY24. Excluding net finance costs from exchange rate differences as well as extraordinary refinancing costs, net finance costs would have been S/459 million in FY25 and S/561 million in FY24, representing a decrease of S/102 million, or 18.2%. The exchange rate difference in FY25 included a positive non-cash amount of S/193 million, compared to a negative S/42 million in FY24.

The positive non-cash amounts in the quarter and full-year primarily reflect the appreciation of the Peruvian Sol against the US Dollar, outside of Auna's call-spread hedge in place during 2025.

**Net Loss** of S/64 million in 4Q25 compared to a S/24 million net gain in 4Q24. On a per-share basis, Auna reported a Net Loss of S/0.92, based on a weighted average number of basic and diluted shares of 74,188,937. In FY25, Net Income was S/111 million compared to S/124 million in FY24. On a per-share basis, annual Net Income was S/1.32 based on a weighted average number of basic and diluted shares of 74,203,227.

**Adjusted Net Income** was S/136 million in 4Q25 versus Adjusted Net Income of S/36 million in 4Q24. On a per-share basis, Auna reported Adjusted Net Income of S/1.78. In FY25 Adjusted Net Income was S/336 million compared to S/146 million in FY24. On a per-share basis, annual Adjusted Net Income was S/4.36.

Business performance

**HEALTHCARE SERVICES MEXICO** 

*(Explanations of variances are in local currency unless expressed otherwise)*

Auna's Healthcare Services and Auna Seguros' operations in Mexico accounted for 23% of consolidated revenues and 27% of consolidated Adjusted EBITDA.

*(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)*

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| |  | | | | **Δ 4Q'25<br> vs 4Q'24** | **Δ 4Q'25<br> vs 4Q'24** | **Δ 4Q'25<br> vs 3Q'25** | **Δ 4Q'25<br> vs 3Q'25** | **Δ FY 25<br> vs FY 24** | **Δ FY 25<br> vs FY 24** |
| <br>**Healthcare Services Mexico<br> Key Operating Metrics** | | <br>**4Q'25 (USD)** | <br>**4Q'25** | <br>**FY 25** | **As<br> Reported**  | **L.C.** | **As<br> Reported**  | **L.C.** | **As<br> Reported**  | **L.C.** |
| Beds | # |  | 708 | 708 | 0% |  | 0% |  | 0% |  |
| Surgeries | *# (000)* |  | 4 | 19 | -17% |  | -19% |  | -10% |  |
| Emergency treatments | *# (000)* |  | 8 | 31 | -18% |  | 10% |  | -15% |  |
| Operating capacity utilization | % |  | 55.7% | 58.0% | -9.4 p.p. |  | -3.0 p.p. |  | -5.7 p.p. |  |
| Total capacity utilization | % |  | 37.1% | 38.6% | -6.2 p.p. |  | -2.0 p.p. |  | -3.8 p.p. |  |
| **Key Financial Metrics** |  |  |  |  |  |  |  |  |  |  |
| Segment Revenue |  | 77 | 258 | 1039 | -4% | -3% | -2% | 0% | -13% | -4% |
| Segment Adjusted EBITDA |  | 18 | 59 | 304 | -37% | -36% | -23% | -21% | -26% | -18% |
| *Segment Adjusted EBITDA margin* | *%* |  | *22.8%* | *29.3%* | *-11.8 p.p.* |  | *-6.2 p.p.* |  | *-5.1 p.p.* |  |

---

**Segment revenue from Mexico** decreased 3% YoY in 4Q25, mainly due to: (i) the of legacy physician and supplier relationships; and (ii) lagged recovery in surgery and emergency volumes, consequently impacting hospitalization days, intensive care unit ("ICU") volumes and general capacity utilization. Although surgery and emergency volumes declined, the lower revenues were partially offset by the rapid expansion of oncology services delivered since the acquisition of Opción Oncología's physician practice. Notably, Auna's revenues from radiotherapy and chemotherapy grew 35% in 4Q25 vs 3Q25, representing 9% of Mexico's network revenues, up from 3% in 4Q24. This is a validation of the vertical integration strategy in Mexico. Further, Auna Seguros contributed to the quarter with a revenue increase of 3% versus 4Q24. Revenue was flat versus 3Q25, reflecting a stabilization of the Mexican operations.

Auna's commitment to further developing relationships with large payors in Mexico was evident when Auna obtained preferred provider tier status that will improve 2026 volumes. In addition, Auna was awarded an extension to serve ISSSTELEON healthcare plan, the social security of state employees and their families, under significantly improved commercial terms; this contract represented approximately 6% of Auna revenues in Mexico in 2025. Both developments are significant accomplishments and will result in higher volumes and revenues in 2026.

**Segment Adjusted EBITDA** decreased 36% YoY in 4Q25 and 18% in the FY25, with a 4Q25 margin of 22.8% and FY25 margin of 29.3%. The decline in adjusted EBITDA was mainly due to lower revenues, and an increase in the cost of treatments and service mix through the 2025 ISSSTELEON healthcare plan, impacting lower gross profit and margin. Adjusted EBITDA also decreased due to overhauling of the organization during 2025, including payroll expenses related to talent, and administrative expenses related to SAP licenses and the systems implementation at Doctors Hospital.

**Update on Key Initiatives in Mexico**

Auna continues to strengthen its healthcare network and enhance execution in Mexico, which we believe remains a large and underpenetrated market, with ongoing investments in technology, talent, and infrastructure. These steps should position the Company to capture the market's long-term growth potential while supporting a return to sustainable growth in 2026.

---

| | |
|:---|:---|
| **1-** | **Leadership and Organization** |

---

Following the completion of key senior management hires in Mexico, the new leadership team is fully aligned and incentivized to restore growth, strengthen commercial execution, and enhance clinical performance. Early progress in recent months reflects the impact of these efforts and the initiatives outlined below. Auna will continue investing in talent across the organization, with particular emphasis on expanding and reinforcing its clinical workforce to support care teams, clinical quality, and operational scalability.

---

| | |
|:---|:---|
| **2-** | **Out-of-Pocket, Corporate Segments, and Institutional Packages** |

---

The Company continues expanding its participation across key market segments through packaged service offerings and closer collaboration with leading physicians to broaden the revenue base and improve capacity utilization. In the Out-of-Pocket segment, revenue share reached 12% in December, supported by targeted pricing initiatives and pre-negotiated physician rates. On the Institutional segment, Auna was awarded an extension of an improved healthcare plan for ISSSTELEON, resulting in a double-digit price improvement that strengthens the margin profile of the partnership.

---

| | |
|:---|:---|
| **3-** | **Payors** |

---

The AunaWay model is closely aligned with payor priorities related to cost containment and value-based care. Through clinical standardization, disciplined procurement, and closer alignment of physician incentives, Auna actively manages medical supply and professional fees while preserving quality patient outcomes. The Company's growing relationships with payors and their patients, demonstrated by its new preferred tier classification, are meaningful contributors to growing the revenue base in 2026 across key service lines, directly addressing prior volume headwinds while maintaining profitability of the Mexico business in 2026.

---

| | |
|:---|:---|
| **4-** | **Physician Engagement and Productivity** |

---

Auna's network of physicians continues to grow and its incentive models have led to a series of productivity and quality initiatives that are gaining additional momentum. In the fourth quarter, management reached approximately 250 physicians, representing 80% of network revenue, to incentivize an increase in medical services delivered by the hospital network. Additionally, the Company continues to attract and recruit new medical and nursing talent in high-complexity procedures.

---

| | |
|:---|:---|
| **5-** | **Oncology Business** |

---

Oncocenter, Auna's oncology Center of Excellence, which was inaugurated in 4Q25, is expanding its successful and dedicated oncology team, with the objective of doubling medical staff and prioritizing physicians who concentrate their clinical practice within Auna's healthcare facilities. This effort is supported by an agreement with a leading insurance provider that includes targeted deductible structures and financial incentives to direct policyholders to its oncology services. These initiatives are expected to drive growth in high-complexity case volumes and improve utilization of Auna's specialized oncology capacity.

The above actions form part of Auna's broader strategy to strengthen its healthcare platform in Mexico, enhance patient care, drive sustainable operational improvements across its facilities, and capture the significant long-term growth opportunity in the market.

**PERU OPERATIONS: HEALTHCARE SERVICES PERU AND ONCOSALUD PERU**

Auna's Healthcare Services and Oncosalud Peru accounted for 43% of consolidated revenues and 50% of consolidated Adjusted EBITDA.

*(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)*

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Healthcare Services Peru and <br> Oncosalud Peru<br> Key Financial Metrics** | **4Q'25<br> (USD)**  | **4Q'25** | **FY 25** | **Δ 4Q'25<br> vs 4Q'24**  | **Δ 4Q'25<br> vs 3Q'25**  | **Δ FY 25<br> vs FY 24**  |
| **Revenue** | **145** | **489** | **1912** | **11%** | **0%** | **9%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Healthcare Services Peru* | 81 | 273 | 1084 | *11%* | *-2%* | *9%* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Oncosalud Peru* | 90 | 304 | 1164 | *10%* | *3%* | *9%* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Holding and Eliminations (\*)* |  | (87) | (337) | *10%* | *3%* | *6%* |
| **Consolidated Peru Adjusted EBITDA** | **33** | **109** | **423** | **14%** | **-1%** | **14%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Healthcare Services Peru* | 8 | 29 | 148 | *21%* | *-35%* | *6%* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Oncosalud Peru* | 24 | 81 | 275 | *12%* | *20%* | *19%* |
| ***Consolidated Peru Adj. EBITDA margin*** *%*** |  | ***22.4%*** | ***22.1%*** | ***0.7 p.p.*** | ***-0.3 p.p.*** | ***0.9 p.p.*** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Healthcare Services Peru* |  | *10.5%* | *13.6%* | *0.8 p.p.* | *-5.2 p.p.* | *-0.3 p.p.* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Oncosalud Peru* |  | *26.7%* | *23.6%* | *0.6 p.p.* | *3.8 p.p.* | *2.0 p.p.* |

---

(\*) Relates to intersegment revenue elimination.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Healthcare Services Peru<br> Key Operating Metrics** | | **4Q'25 (USD)** | **4Q'25** | **FY 25** | **Δ 4Q'25<br> vs 4Q'24**  | **Δ 4Q'25<br> vs 3Q'25**  | **Δ FY 25<br> vs FY 24**  |
| Beds | # |  | 385 | 385 | 3% | 0% | 3% |
| Surgeries | *# (000)* |  | 5 | 21 | -1% | -1% | 2% |
| Emergency treatments | *# (000)* |  | 48 | 182 | 7% | -2% | 2% |
| Operating capacity utilization | % |  | 76.4% | 75.7% | -0.9 p.p. | -1.6 p.p. | -6.1 p.p. |
| Total capacity utilization | % |  | 74.8% | 74.1% | 7.2 p.p. | -1.2 p.p. | 2.6 p.p. |
| **Key Financial Metrics** |  |  |  |  |  |  |  |
| Revenue |  | 81 | 273 | 1084 | 11% | -2% | 9% |
| &nbsp;&nbsp;&nbsp;*External revenues* |  | 59 | *197* | *786* | 12% | -2% | 9% |
| &nbsp;&nbsp;&nbsp;*Intercompany revenue* |  | 23 | *76* | *298* | 10% | -2% | 7% |
| Segment Adjusted EBITDA |  | 8 | 29 | 148 | 21% | -35% | 6% |
| *Segment Adjusted EBITDA margin* | % |  | *10.5%* | *13.6%* | *0.8 p.p.* | *-5.2 p.p.* | *-0.3 p.p.* |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Oncosalud Peru<br> Key Operating Metrics** | | **4Q'25 (USD)** | **4Q'25** | **FY 25** | **Δ 4Q'25<br> vs 4Q'24**  | **Δ 4Q'25<br> vs 3Q'25**  | **Δ FY 25<br> vs FY 24**  |
| Plan memberships | *# (000)* |  | 1425 | 1425 | 4% | 2% | 4% |
| &nbsp;&nbsp;&nbsp;*Oncological Plans* | *# (000)* |  | *991* | *991* | -1% | 0% | -1% |
| Average monthly revenue per plan membership |  | 18.86 | 63.44 | 61.12 | 4% | 2% | 4% |
| Preventive check-ups | *# (000)* |  | 27 | 121 | -3% | -6% | 14% |
| Patients treated | *# (000)* |  | 9 | 74 | 53% | -26% | 27% |
| MLR | % |  |  | 54.2% |  |  | -3.1 p.p. |
| &nbsp;&nbsp;&nbsp;*Oncological Plans* | *%* |  |  | *48.5%* |  |  | *-4.4 p.p.* |
| **Key Financial Metrics** |  |  |  |  |  |  |  |
| Revenue |  | 90 | 304 | 1164 | 10% | 3% | 9% |
| &nbsp;&nbsp;&nbsp;*External revenues* |  | *87* | *292* | *1125* | *10%* | 2% | *9%* |
| &nbsp;&nbsp;&nbsp;*Intercompany revenue* |  | *3* | *12* | *39* | *13%* | 61% | *-3%* |
| Segment Adjusted EBITDA |  | 24 | 81 | 275 | 12% | 20% | 19% |
| *Segment Adjusted EBITDA margin* | % |  | *26.7%* | *23.6%* | *0.6 p.p.* | *3.8 p.p.* | *2.0 p.p.* |

---

**Total revenue from Peru** increased 11% YoY to S/489 million in 4Q25. The Healthcare Services segment increased revenues by 11% YoY, reflecting an increase in revenues from surgeries, emergency visits and ambulatory care, including chemotherapy services, and driven by increased ticket and service volumes generated from new medical equipment, additional hospitalization beds and marketing efforts in the network.

Operating capacity utilization in 4Q25 was 76.4%, while total capacity utilization was 74.8%. In 2Q25, Auna updated the number of operating beds at Clínica Delgado, Clínica Vallesur and Clínica Miraflores in Piura, adding 10 beds to total capacity. As a result, hospitalization days increased, as reflected in total capacity utilization expanding 7.2 p.p. YoY. Operating capacity utilization in the FY25 was 75.7%, a decrease of 6.1 p.p. due to the partial recognition of hospitalization days in FY25 against the updated number of beds.

The 10% YoY increase in revenues at the Oncosalud Peru segment reflects a 4% increase in total plan memberships and the effect of price adjustments to achieve MLR objectives.

Commercial initiatives to grow the B2B segments and value-added initiatives, which add tangible value to membership holders, have been implemented.

Oncosalud's MLR decreased 3.1 p.p. to 54.2%, led by the Oncology MLR, which decreased for a sixth consecutive quarter to 48.5%, or 4.4 p.p. The MLR decrease was driven by lower average treatment costs, and despite an increase in patients treated, the operation continues to generate scale efficiencies from the pharmaceutical side.

In FY25, revenues increased 9% compared to FY24, supported equally by increases in ticket and volumes in healthcare services and the aforementioned ticket increase in oncology plan memberships.

**Consolidated Adjusted EBITDA in Peru** increased 14% YoY to S/109 million in 4Q25, with a margin of 22.4%, an increase of 0.7 p.p. from 4Q24. In FY25, Adjusted EBITDA increased 14% from FY24, with a margin of 22.1%, an increase of 0.9 p.p. from FY24.

**HEALTHCARE SERVICES COLOMBIA**

*(Explanations of variances are in local currency unless expressed otherwise)*

Auna's Healthcare services operations in Colombia accounted for 34% of consolidated revenues and 23% of consolidated Adjusted EBITDA.

*(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)*

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| |  | | | | **Δ 4Q'25<br> vs 4Q'24** | **Δ 4Q'25<br> vs 4Q'24** | **Δ 4Q'25<br> vs 3Q'25** | **Δ 4Q'25<br> vs 3Q'25** | **Δ FY 25<br> vs FY 24** | **Δ FY 25<br> vs FY 24** |
| <br>**Healthcare Services Colombia<br> Key Operating Metrics** | | <br>**4Q'25 (USD)** | <br>**4Q'25** | <br>**FY 25** | **As<br> Reported**  | **L.C.** | **As<br> Reported**  | **L.C.** | **As<br> Reported**  | **L.C.** |
| Beds | # |  | 1131 | 1131 | 0% |  | 0% |  | 0% |  |
| Surgeries | *# (000)* |  | 10 | 43 | -8% |  | -7% |  | -9% |  |
| Emergency treatments | *# (000)* |  | 35 | 145 | -3% |  | -5% |  | -4% |  |
| Operating capacity utilization | % |  | 86.1% | 86.5% | -1.9 p.p |  | -0.4 p.p |  | -3.5 p.p |  |
| Total capacity utilization | % |  | 76.3% | 76.6% | -2.6 p.p |  | -0.8 p.p |  | -3.0 p.p |  |
| **Key Financial Metrics** |  |  |  |  |  |  |  |  |  |  |
| Segment Revenue |  | 115 | 387 | 1440 | 9% | 7% | 5% | 5% | 0% | 5% |
| Segment Adjusted EBITDA |  | 15 | 50 | 201 | -23% | -25% | -1% | -2% | -8% | -4% |
| *Segment Adjusted EBITDA margin* | *%* |  | *13.1%* | *13.9%* | *-5.6 p.p* |  | *-0.8 p.p* |  | *-1.2 p.p.* |  |

---

**Segment revenue from Colombia** in 4Q25 grew 7% YoY, primarily due to the gradual implementation of risk-sharing models in Antioquia and Monteria, including risk-sharing models for cardiovascular, ambulatory, and oncology services. Risk-sharing models revenues accounted for 21% of Colombia's total revenues in 4Q25, increasing from 17% in 4Q24. Surgery volumes and emergency treatments declined as a result of services provided to the intervened payors, however, higher tickers in surgery and emergency treatments more than offset the lower volumes. Continued growth in chemotherapy and imaging services also contributed to top-line growth.

Auna continues diversifying its payor base as part of the strategy to limit revenues and cashflows from government-intervened payors. The share of revenues from the government-intervened payor Nueva EPS was 13%, decreasing from 21% in 4Q24.

Revenues in FY25 increased 5% versus FY24, due to ticket increases for key services that offset volume losses and to the implementation of a commercial strategy that prioritized cashflows over growth during the year.

In Q425, operating capacity utilization was 86.1%, a YoY decrease of 1.9 p.p., while total capacity utilization was 76.3%, a YoY decrease of 2.6 p.p. from 4Q24. On a full-year basis, operating capacity utilization declined 3.5 p.p. to 86.5% and total capacity utilization declined 3.0 p.p. to 76.6%. The lower levels of capacity utilization are a direct outcome of proactively managing contracted services with government-intervened payors to prioritize cash generation over revenue growth.

**Segment Adjusted EBITDA** in 4Q25 decreased 25%, with a margin decrease of 5.6 p.p. to 13.1%, and in FY25 decreased 4%, with a margin decrease of 1.2 p.p. to 13.9%. The decreases in Adjusted EBTIDA were due to extraordinary items in 4Q24, including price adjustments for services provided during 2024 and year-end recognition of procurement rebates. Adjusted EBITDA was in line with 3Q25, declining only 1%, as well as margin which was 0.80 p.p. down, demonstrating the stabilization in results following the change in payor mix in 2025.

Balance Sheet & Cash Flow

In 4Q25, Auna successfully completed a USD 825 million debt refinancing through its relationship banks, institutional investors and the International Finance Corporation. New 8.75% 2032 Senior Secured Notes were issued at par for USD 365 million. The refinancing also included a new USD 460 million Term Loan maturing in 2030, comprising an MXN tranche for USD 400 million and a PEN tranche for USD 60 million. In addition to improving Auna's maturity profile, lowering interest expenses, increasing the proportion of direct local currency funding, and increasing financial flexibility, the refinancing represents an important milestone toward reducing Net debt-to-EBITDA to 3.0x.

**Consolidated Debt** 

*(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Dec-25<br> (USD)** | **Dec-25** | **Dec-24** | |
|  | **Dec-25<br> (USD)** | **Dec-25** | **Dec-24** | **Δ Dec-25 vs**<br>**Dec-24** |
| &nbsp;&nbsp;&nbsp;(+) Loans and borrowings | 1050 | 3533 | 3620 | -2% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Short term debt* | *94* | *316* | *654* | -52% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Long term debt* | *956* | *3216* | *2966* | 8% |
| &nbsp;&nbsp;&nbsp;(+) Lease Liabilities | 37 | 124 | 148 | -16% |
| **Gross Debt** | **1087** | **3656** | **3768** | **-3%** |
| &nbsp;&nbsp;&nbsp;(-) Cash and cash equivalents / marketable securities | 100 | 335 | 236 | 42% |
| **Net Debt** | **987** | **3321** | **3532** | **-6.0%** |
| **Leverage Ratio** |  | **3.6x** | **3.6x** | **0x** |

---

**Gross Debt** at the close of 4Q25 decreased 3%, or S/112 million, versus 4Q24 to S/3,656 million.

While the 4Q25 refinancing was a debt neutral transaction, the impact of repurchase premiums and fees and expenses resulted in an increase of S/72 million, and included, i) the partial repayment of the 2029 Notes inclusive of S/65 million of premiums paid; ii) the full repayment of the Credit Agreement dated November 10, 2023, and iii) reduction of short-term debt in line with the Company´s strategy to restructure its short-term obligations. As of year-end, the debt related to the New Term Loan maturing 2030 is S/1,569 million and the debt related to the Senior Secured Notes due 2032 is S/1,563 million.

Conversely, gross debt decreased S/125 million, mainly due to an 11% appreciation of the PEN/USD exchange rate, as well as, a reduction of S/58 million in long-term debt and financial and operating leasing.

**Leverage Ratio** was 3.6x, unchanged at the end of 4Q25 compared to year-end 2024. This reflects lower Adjusted EBITDA, reduced gross debt as well as higher cash levels despite the extraordinary expenses and premiums incurred as part of the refinancing exercise. Auna remains committed to a medium-term leverage target of less than 3.0x.

**Consolidated Debt Amortization Profile** 

*(Figures in millions of Soles, unless expressed otherwise)*

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Total** | **Leases** | **Y1** | **Y2** | **Y3** | **Y4** | **Y5** | **Y6+** |
| Loans and Borrowings | 3533 |  | 316 | 38 | 192 | 252 | 716 | 2018 |
| Financial Leases | 47 |  | 15 | 19 | 4 | 3 | 3 | 5 |
| Operating Leases | 76 | 76 |  |  |  |  |  |  |
| **Gross Debt** | **3656** | **76** | **331** | **56** | **196** | **254** | **719** | **2023** |

---

As of 4Q25. Excludes interest. Reflects figures post-refinancing. Y1 = January 2026 to December 2026, Y2 = January 2027 to December 2027, Y3 = January 2028 to December 2028, Y4 = January 2029 to December 2029, Y5 = January 2030 to December 2030, and Y6+ = January 2031 to September 2035.

**Cashflow and Cash Conversion Cycle**

*(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **FY 25<br> (USD)**  | **FY 25** | **FY 24** | **Δ FY 25 vs<br> FY 24**  |
| **Net cash from operating activities** | **197** | **663** | **668** | **-1%** |
| **Net cash used in investing activities** | **(24)** | **(80)** | **(237)** | **-66%** |
| **Net cash used in financing activities** | **(145)** | **(487)** | **(418)** | **16%** |
| **Cash and cash equivalents at the end of the period** | **100** | **335** | **236** | **42%** |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **LTM Dec-24** | **LTM Sep-25** | **LTM Dec-25** |
| Days Sales Outstanding | 83 | 89 | 90 |
| Days Inventory Outstanding | 39 | 42 | 42 |
| Days Payable Outstanding | 123 | 132 | 131 |
| **Cash Conversion Cycle** | **-1** | **0** | **1** |

---

\*Measured on an average basis according to last twelve months results.

Net cash from operating activities was S/663 million for the twelve months ended December 31, 2025 versus S/668 million in the twelve months ended December 31, 2024, and included: (i) a S/15 million increase in cash generated from operating activities, even in the context of S/12 million in performance-based bonuses paid to Opción Oncología doctors and the impacts related to the information system migration in Mexico; (ii) a S/6 million decrease in net interest received, and (iii) a S/15 million increase in income taxes paid. While the migration to new information systems increased accounts receivable days versus 2024, this impact was stabilized in 4Q 2025.

Net cash used in investing activities decreased 66% YoY, or S/157 million, to S/80 million for the twelve months ended December 31, 2025 versus the comparable period last year, and included: (i) S/145 million in organic maintenance CapEx, relatively flat to 2024, including S/86 million in infrastructure CapEx; S/51 million in SAP and Hospital Information Systems implementations, S/8 million for a branding rights payment to Opción Oncología doctors. Investing activities also included (ii) a S/15 million payment to former OCA shareholders for holdback obligations, (iii) a S/6 million earnout payment to IMAT Oncomedica shareholders, and (iv) S/ 10 million related to other activities, including the disposal of a property in Mexico. In addition, (v) Auna Seguros rebalanced its portfolio of investments toward liquid securities, resulting in S/76 million in cash and cash equivalent inflows. In the twelve months ended December 31, 2024, investing activities included: (i) S/163 million in organic maintenance CapEx, including S/21 million for Auna Seguros reserve requirements, (ii) a S/47 million earnout payment to IMAT Oncomedica shareholders, and (iii) a S/30 million payment to OCA shareholders.

Net cash used in financing activities was S/487 million, an increase of 16% YoY, or S/69 million, for the twelve months ended December 31, 2025 versus the comparable period last year. Cash used in financing activities during the period included: (i) S/392 million in interest and hedge premium payments, (ii) S/62 million in interest payments for working capital facilities, and (iii) a S/31 million increase in working capital borrowings. Excluding extraordinary refinancing transaction costs of S/46 million and premiums paid of S/65 million related to the 2029 Notes tender offer refinancing, financing activities would have been S/ 376 million including short- and long-term debt interest payments, representing a reduction in interest expense and increased interest coverage. For the comparable twelve months ended December 31, 2024, cash used included S/502 million in interest and hedge premium payments, partially offset by net IPO proceeds of S/17 million and related refinancing activities.

Recent Developments

In February 2026, Auna obtained authorization to commence the refurbishment, completion and opening of Centro Ambulatorio Trecca in Lima, an ambulatory facility that transform how it will serve up to 3 million EsSalud beneficiaries annually. This Public-Private Partnership (PPP) agreement with EsSalud (Seguro Social del Perú), Peru's social security institution, will result in Peru's largest outpatient facility, a 23-story, high-complexity center that will span 59,000 square meters and is designed to support over three million patient visits annually, expanding EsSalud's metropolitan capacity by approximately 20%. The project aligns with the AunaWay strategy by broadening the Company's addressable market to include EsSalud's six million insured members. Structured under a concession framework through 2046 (renewable to 2064), the project features a predictable revenue model with guaranteed minimum monthly payments and a de-risked capital structure; construction expenditures are reimbursed by EsSalud through sovereign-backed progress certificates, requiring limited upfront investment from Auna.

Completion of the facility is expected in early 2028 and anticipated to be operational in mid-2028.

**About AUNA**

Auna is a leading healthcare platform in Latin America with operations in Mexico, Peru, and Colombia, prioritizing prevention and concentrating on high-complexity diseases that contribute the most to healthcare expenditures. Our mission is to transform healthcare by providing access to a highly integrated healthcare offering in the underpenetrated markets of Spanish-Speaking Americas. Founded in 1989, Auna has built one of Latin America's largest modern healthcare platforms that consists of a horizontally integrated network of healthcare facilities and a vertically integrated portfolio of oncological plans and selected general healthcare plans. As of December 31, 2025, Auna's network included 31 healthcare network facilities, consisting of hospitals, outpatient, prevention and wellness facilities with a total of 2,333 beds, and 1.4 million healthcare plans.

For more information visit www.aunainvestors.com

Conference Call Details

**When:** 8:00 a.m. Eastern time, March 11, 2026

**Who:** Mr. Suso Zamora, Executive Chairman of the Board and President; Mrs. Gisele Remy, Chief Financial Officer and Executive Vice President; Mr. Lorenzo Massart, Executive Vice President of Strategy and Equity Capital Markets.

**Dial-in:** +1 888 596 4144 (U.S. domestic), +1 646 968 2525 (International)<br> **Passcode:** 3884034

To access Auna's financial results call via telephone, callers need to press # to be connected to an operator.

**Webcast:** <u>click here</u> (https://events.q4inc.com/attendee/925999779)

**Definitions and Concepts**

Figures in US dollars (US$ or USD) for 3Q25 are presented for indicative purposes and were calculated using an FX rate of US$1= S/3.363. All comparisons in this announcement are year-over-year ("YoY"), unless otherwise noted; additionally, results are presented in an FX neutral basis ("FXN") for consolidated revenues, consolidated cost of sales and services, consolidated selling and administrative expenses and consolidated adjusted

EBITDA, as well as, in local currency for the Mexico and Colombia segments, to eliminate the effect of foreign exchange, or "FX," volatility between the comparison periods.

Financial results are preliminary and subject to year-end audit.

**Use of Non-IFRS Financial Measures**

This release includes financial measures defined as "non-IFRS financial measures" by the SEC, including: EBITDA, EBITDA Margin, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted LTM EBITDA, Segment EBITDA, Segment EBITDA Margin, Segment Adjusted EBITDA, Segment Adjusted EBITDA Margin, Consolidated Peru Adjusted EBITDA, Consolidated Peru Adjusted EBITDA Margin, Adjusted Net Income, Basic and Diluted EPS, Adjusted Basic and Diluted EPS, Leverage Ratio and FX Neutral because we believe they assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance.

In addition, management and our board of directors use these non-IFRS financial measures to assess our financial performance and believe they are helpful in highlighting trends in our core operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding the growth of our business. These are not measures of operating performance under IFRS and have limitations as analytical tools. You should not consider such measures either in isolation or as substitutes for analyzing our results as reported under IFRS. Additionally, our calculations of EBITDA, Segment EBITDA, Adjusted EBITDA, Adjusted Net Income, EBITDA Margin, Adjusted EBITDA Margin, Adjusted Net Income Margin, FX Neutral and Leverage Ratio may be different from the calculations used by other companies for similarly titled measures, including our competitors, and therefore may not be comparable to those of other companies.

**EBITDA:** is calculated as profit (loss) before tax for the period plus net finance cost and depreciation and amortization. EBITDA is a key metric used by management and our board of directors to assess our financial performance.

**EBITDA Margin:** is calculated as EBITDA divided by total revenue from contracts with customers.

**Adjusted EBITDA:** is calculated as profit (loss) before tax for the period plus net finance cost, depreciation and amortization, pre-operating expenses for projects under construction, business development (income) expenses for expansion into new markets, change in fair value of earn-out liabilities, stock-based consideration and personnel non-recurring compensation.

**Adjusted EBITDA Margin:** is calculated as Adjusted EBITDA divided by total revenue from contracts with customers.

**Adjusted Last Twelve Month ("LTM") EBITDA**: is calculated by adding the last four quarters beginning with the corresponding period.

**Segment EBITDA:** is calculated as segment profit before tax plus net finance cost and depreciation and amortization.

**Segment EBITDA Margin:** is calculated as segment EBITDA divided by total segment revenue from contracts with customers.

**Segment Adjusted EBITDA:** is calculated as segment profit (loss) before tax for the period plus net finance cost, depreciation and amortization, pre-operating expenses for projects under construction, business development (income) expenses for expansion into new markets, change in fair value of earn-out liabilities, stock-based consideration and personnel non-recurring compensation.

**Segment Adjusted EBITDA Margin**: is calculated as segment Adjusted EBITDA divided by total Segment revenue from contracts with customers.

*(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)*

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **4Q'25<br> (USD)** | | | **Δ 4Q'25 vs** | **Δ 4Q'25 vs** | **Δ FY 25 vs** |
| | **4Q'25<br> (USD)** | <br>**4Q'25** | <br>**FY 25** | **4Q'24** | **3Q'25** | **FY 24** |
| <br>**Revenues** | **337** | **1133** | **4385** | **7%** | **1%** | **0%** |
| **Profit (Loss) before Tax** | **(27)** | **(91)** | **199** | **-345%** | **-194%** | **8%** |
| (+) Net Finance Cost | 71 | 238 | 436 | 53% | 231% | -28% |
| (+) Depreciation and Amortization | 17 | 56 | 222 | 9% | -2% | 1% |
| **(=) EBITDA** | **60** | **203** | **858** | **-17%** | **-10%** | **-15%** |
| (+) Adjustments | 5.2 | 17.5 | 58.4 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(a) Pre-operating expenses* | 0.0 | *0.0* | *0.5* |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(b) Business development expenses* | 2.8 | *9.6* | *41.0* |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(c) Stock-based consideration* | 0.8 | *2.9* | *11.2* |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(d) Personnel non-recurring compensation* | *1.5* | *5.0* | *5.7* |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(e) Change in fair value of investment properties* |  | *0.0* | *0.0* |  |  |  |
| **(=) Adjusted EBITDA** | **66** | **220** | **917** | **-13%** | **-5%** | **-8%** |
| *Adjusted EBITDA Margin* |  | *19.5%* | *20.9%* | *-4.5 p.p.* | *-1.3 p.p.* | *-1.7 p.p.* |

---

(a) Pre-operating expenses consist of legal and administrative expenses incurred in connection with medical facilities under construction, such as Clínica Chiclayo, costs relating to the Centro Ambulatorio Trecca PPP, and legal and administrative expenses incurred in connection with the acquisition of land banks for future facilities.

(b) Business development expenses consist of expenses incurred in connection with projects and payments to sellers to expand into new markets, including through greenfield projects and M&A activity.

(c) Stock-based consideration includes share-based payments plans for non-executive members of the Board of Directors and other Auna management including executives and employees.

(d) Personnel non-recurring compensation related to the implementation of an efficiency program across business units aimed at streamlining processes and capturing synergies on the local and regional levels.

(e) Change in fair value of investment properties includes the non-cash effect related to the decrease or increase in the fair value of investment properties.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **For the three months ended December 31, 2025** | **For the three months ended December 31, 2025** | | | | | |
|  | **Healthcare Services Mexico** | <br>**Healthcare Services Peru** | <br>**Oncosalud Peru** | <br>**Healthcare Services Colombia** | <br>**Holding and eliminations** | <br>**Consolidated Reportable Segments** |
| **Revenues** | **258** | **273** | **304** | **387** | **(89)** | **1133** |
| **Profit (Loss) before Tax** | **(91)** | **4** | **54** | **29** | **(87)** | **(91)** |
| (+) Net Finance Cost | 124 | 6 | 2 | 9 | 97 | 238 |
| (+) Depreciation and Amortization | 21 | 13 | 9 | 11 | 3 | 56 |
| **(=) Segment EBITDA** | **54** | **23** | **65** | **48** | **13** | **203** |
| (+) Adjustments | 4.9 | 5.7 | 16.2 | 2.4 | -11.7 | 17.5 |
| Pre-operating expenses | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* |
| Business development expenses | *1.7* | *2.9* | *3.4* | *1.5* | *0.0* | *9.6* |
| Change in fair value of earn-out liabilities | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* |
| Stock-based consideration | *1.8* | *0.2* | *0.2* | *0.1* | *0.6* | *2.9* |
| Personnel non-recurring compensation | *1.4* | *1.4* | *1.4* | *0.8* | *0.0* | *5.0* |
| Change in fair value of investment properties | *0.0* | *1.2* | *11.2* | *0.0* | *-12.3* | *0.0* |
| **(=) Segment Adjusted EBITDA** | **59** | **29** | **81** | **50** | **1** | **220** |
| Adjusted EBITDA Margin | 22.8% | 10.5% | 26.7% | 13.1% |  | 19.5% |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **For the three months ended December 31, 2024** | **For the three months ended December 31, 2024** | | | | | |
|  | **Healthcare Services Mexico** | <br>**Healthcare Services Peru** | <br>**Oncosalud Peru** | <br>**Healthcare Services Colombia** | <br>**Holding and eliminations** | <br>**Consolidated Reportable Segments** |
| **Revenues** | **268** | **245** | **276** | **353** | **(79)** | **1063** |
| **Profit (Loss) before Tax** | **18** | **(2)** | **46** | **3** | **(28)** | **37** |
| (+) Net Finance Cost | 49 | 13 | 15 | 52 | 27 | 155 |
| (+) Depreciation and Amortization | 19 | 11 | 9 | 10 | 3 | 52 |
| **(=) Segment EBITDA** | **86** | **22** | **70** | **64** | **2** | **244** |
| (+) Adjustments | 6.8 | 1.6 | 1.7 | 1.5 | -1.6 | 10.0 |
| Pre-operating expenses | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* |
| Business development expenses | *0.1* | *0.0* | *0.0* | *0.1* | *2.4* | *2.6* |
| Change in fair value of earn-out liabilities | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* |
| Stock-based consideration | *5.7* | *0.5* | *0.6* | *0.1* | *-4.0* | *2.9* |
| Personnel non-recurring compensation | *1.1* | *1.1* | *1.1* | *1.3* | *0.0* | *4.6* |
| Change in fair value of investment properties | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* |
| **(=) Segment Adjusted EBITDA** | **93** | **24** | **72** | **66** | **0** | **254** |
| Adjusted EBITDA Margin | 34.7% | 9.6% | 26.1% | 18.6% |  | 23.9% |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | <br>**Healthcare Services Mexico** | <br>**Healthcare Services Peru** | <br>**Oncosalud Peru** | <br>**Healthcare Services Colombia** | <br>**Holding and eliminations** | <br>**Consolidated Reportable Segments** |
| **Year to date December 31, 2025**<br>**Revenues** | **1039** | **1084** | **1164** | **1440** | **(342)** | **4385** |
| **Profit (Loss) before Tax** | **(50)** | **58** | **206** | **134** | **(149)** | **199** |
| (+) Net Finance Cost | 230 | 34 | 15 | 22 | 136 | 436 |
| (+) Depreciation and Amortization | 86 | 49 | 36 | 41 | 11 | 222 |
| **(=) Segment EBITDA** | **266** | **140** | **257** | **197** | **(2)** | **858** |
| (+) Adjustments | 37.4 | 7.8 | 18.3 | 4.3 | -9.5 | 58.4 |
| Pre-operating expenses | *0.0* | *0.0* | *0.0* | *0.0* | *0.5* | *0.5* |
| Business development expenses | *28.3* | *4.5* | *5.0* | *3.2* | *0.0* | *41.0* |
| Change in fair value of earn-out liabilities | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* |
| Stock-based consideration | *7.1* | *0.7* | *0.7* | *0.3* | *2.4* | *11.2* |
| Personnel non-recurring compensation | *2.0* | *1.4* | *1.4* | *0.8* | *0.0* | *5.7* |
| Change in fair value of investment properties | *0.0* | *1.2* | *11.2* | *0.0* | *-12.3* | *0.0* |
| **(=) Segment Adjusted EBITDA** | **304** | **148** | **275** | **201** | **-11** | **917** |
| Adjusted EBITDA Margin | 29.3% | 13.6% | 23.6% | 13.9% |  | 20.9% |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | <br>**Healthcare Services Mexico** | <br>**Healthcare Services Peru** | <br>**Oncosalud Peru** | <br>**Healthcare Services Colombia** | <br>**Holding and eliminations** | <br>**Consolidated Reportable Segments** |
| **Year to date December 31, 2024**<br>**Revenues** | **1195** | **996** | **1071** | **1443** | **(318)** | **4386** |
| **Profit (Loss) before Tax** | **65** | **44** | **165** | **(2)** | **(88)** | **184** |
| (+) Net Finance Cost | 285 | 48 | 33 | 176 | 68 | 609 |
| (+) Depreciation and Amortization | 92 | 43 | 33 | 42 | 9 | 219 |
| **(=) Segment EBITDA** | **442** | **135** | **230** | **216** | **(12)** | **1012** |
| (+) Adjustments | (31.8) | 4.4 | 1.7 | 2.2 | 5.0 | (18.4) |
| Pre-operating expenses | *1.9* | *0.0* | *0.0* | *0.0* | *0.3* | *2.3* |
| Business development expenses | *-42.4* | *0.0* | *0.0* | *0.1* | *2.4* | *-39.9* |
| Change in fair value of earn-out liabilities | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* |
| Stock-based consideration | *5.7* | *0.5* | *0.6* | *0.1* | *2.2* | *9.1* |
| Personnel non-recurring compensation | *3.1* | *3.9* | *1.1* | *2.0* | *0.0* | *10.1* |
| Change in fair value of investment properties | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* |
| **(=) Segment Adjusted EBITDA** | **410** | **139** | **232** | **218** | **-7** | **993** |
| Adjusted EBITDA Margin | 34.3% | 14.0% | 21.7% | 15.1% |  | 22.6% |

---

**Consolidated Peru Adjusted EBITDA:** is calculated by adding Healthcare Services Peru segment Adjusted EBITDA plus Oncosalud Peru segment Adjusted EBITDA.

**Consolidated Peru Adjusted EBITDA Margin**: is calculated as Healthcare Services Peru segment Adjusted EBITDA plus Oncosalud Peru segment Adjusted EBITDA, divided by total revenues from Healthcare Services Peru Segment plus total revenues from Oncosalud Peru segment.

**Adjusted Net Income:** is calculated as profit (loss) for the period plus adjustments as described below.

*(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)*

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **4Q'25<br> (USD)**  | **4Q'25** | **4Q'24** | **FY 25** | **FY 24** |
| <br>**Net Income (Loss)** | **(19)** | **(64)** | **24** | **111** | **124** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(a) Pre-operating expenses* | 0.0 | 0.0 | 0.0 | 0.5 | 2.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(b) Business development expenses* | 2.8 | 9.6 | 2.6 | 41.0 | (39.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(c) Stock-based consideration* | 0.8 | 2.9 | 2.9 | 11.2 | 9.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(d) Personnel non-recurring compensation* | 1.5 | 5.0 | 4.6 | 5.7 | 10.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(e) Change in fair value of investment properties* | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(f) Non-cash and non-recurring financial costs* | 55.9 | 187.9 | 5.6 | 188.9 | 35.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(g) Allocated tax effects* | (1.7) | (5.7) | (3.0) | (21.7) | 5.7 |
| **(=) Adjusted Net Income** | **40** | **136** | **36** | **336** | **146** |

---

(a) Pre-operating expenses consist of legal and administrative expenses incurred in connection with medical facilities under construction, such as Clínica Chiclayo, costs relating to the Centro Ambulatorio Trecca PPP, and legal and administrative expenses incurred in connection with the acquisition of land banks for future facilities.

(b) Business development expenses consist of expenses incurred in connection with projects and payments to sellers to expand into new markets, including through greenfield projects and M&A activity.

(c) Stock-based consideration includes share-based payments plans for non-executive members of the Board of Directors and other Auna management including executives and employees.

(d) Personnel non-recurring compensation related to the implementation of an efficiency program across business units aimed at streamlining processes and capturing synergies on the local and regional levels.

(e) Change in fair value of investment properties includes the non-cash effect related to the decrease or increase in the fair value of investment properties.

(f) Non-cash and non-recurring financial costs include; 1) one-time non-recurring costs of refinancing activities; 2) non-cash derivative costs related to mark to market of legacy derivatives related to extinguished financings; 3) non-cash effects related to early extinguishment of financings, and 4) non-cash effects related to the accounting impact of changes in the fair value of the liability for mandatory purchase of shares from IMAT.

(g) Allocated tax effects neutralize the tax shield that the items considered as adjustment have generated in the taxable profit.

**Basic and Diluted Earnings per Share:** Basic and Diluted Earnings per Share is calculated by dividing the profit attributable to owners of the Company by the weighted average number of basic and diluted shares outstanding during the period, which excludes treasury shares.

**Adjusted Basic and Diluted Earnings per Share:** Adjusted Basic and Diluted Earnings per Share is calculated by dividing profit attributable to owners of Adjusted Net Income of the Company by the weighted average number of basic and diluted shares outstanding during the period, which excludes treasury shares.

*(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)*

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **4Q'25<br> (USD)**  | **4Q'25** | **4Q'24** | **3Q'25** | **FY 25** | **FY 24** |
| <br>**Net Income (Loss)** | **(19)** | **(64)** | **24** | **53** | **111** | **124** |
| *Income (Loss) attributable to Owner of the company* | *(20)* | *(68)* | *22* | *48* | *98* | *110* |
| *Weighted average number of basic and diluted shares at December 31* |  | *74.2* | *74.2* | *74.2* | *74.2* | *67.5* |
| ***Basic and diluted earnings per share*** | **(0.27)** | **(0.92)** | **0.30** | **0.65** | **1.32** | **1.63** |
| **Adjusted Net Income (Loss)** | **40** | **136** | **36** | **58** | **336** | **146** |
| *Income (Loss) attributable to owners of Adjusted Net Income* | *39* | *132* | *35* | *53* | *323* | *133* |
| *Weighted average number of basic and diluted shares at December 31* |  | *74.2* | *74.2* | *74.2* | *74.2* | *67.5* |
| ***Adjusted Basic and Diluted Earnings per Share*** | **0.53** | **1.78** | **0.47** | **0.71** | **4.36** | **1.97** |

---

**Leverage Ratio:** We calculate Leverage Ratio as (i) current and non-current loans and borrowings plus current and non-current lease liabilities minus (ii) cash and cash equivalents, divided by (iii) Last twelve months Adjusted EBITDA.

*(Figures in millions of Soles, unless expressed otherwise)*

---

| | | |
|:---|:---|:---|
|  | **Dec-24** | **Dec-25** |
|  | **Dec-24** | **Dec-25** |
| Current and non-current loans & borrowings | 3620 | 3533 |
| Current and non-current lease liabilities | 148 | 124 |
| Cash and cash equivalents | 236 | 335 |
| Net Debt | 3532 | 3321 |
| Adjusted LTM EBITDA | 993 | 917 |
| **Leverage Ratio** | **3.6x** | **3.6x** |

---

**Net Debt:** We calculate Net Debt as Gross Debt minus Cash and cash equivalents.

*(Figures in millions of Soles, unless expressed otherwise)*

---

| | | |
|:---|:---|:---|
|  | **Dec-24** | **Dec-25** |
| &nbsp;&nbsp;&nbsp;(+) Loans and borrowings | 3620 | 3533 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Short term debt* | *654* | *316* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Long term debt* | *2966* | *3216* |
| &nbsp;&nbsp;&nbsp;(+) Lease Liabilities | 148 | 124 |
| **Gross Debt** | **3768** | **3656** |
| &nbsp;&nbsp;&nbsp;(-) Cash and cash equivalents | 236 | 335 |
| **Net Debt** | **3532** | **3321** |

---

**FX Neutral:** FX Neutral ("FXN") measures are prepared and presented to eliminate the effect of foreign exchange, or "FX," volatility between the comparison periods, allowing management and investors to evaluate financial performance despite variations in foreign currency exchange rates, which may not be indicative of core operating results and business outlook.

FX Neutral measures are presented because management believes that these non-IFRS financial measures can provide useful information to investors, securities analysts and the public in their review of operating and financial performance, although they are not calculated in accordance with IFRS or any other generally accepted accounting principles and should not be considered as a measure of performance in isolation.

The FX Neutral measures were calculated to present what such measures in preceding periods would have been had exchange rates remained stable from these preceding periods until the date of the Company's most recent financial information.

The FX Neutral measures for the three months ended December 31, 2024 were calculated by multiplying the as reported amounts of Revenue, Adjusted EBITDA and the key business metrics for such period by the average Mexican pesos / Peruvian soles exchange rate for the three months ended December 31, 2024 (MXN 5.3450 to PEN 1.00) and the average Colombian pesos / Peruvian soles exchange rate for the three months ended December 31, 2024 (COP 1,157.2098 to PEN 1.00); then using such results to re-

translate the corresponding amounts back to Peruvian soles by dividing them by the average Mexican pesos / Peruvian soles and Colombian pesos / Peruvian soles exchange rate for the three months ended December 31, 2025 (MXN 5.4086 to PEN 1.00 / COP 1,128.3341 to PEN 1.00), so as to present what certain of statement of profit and loss amounts and key business metrics would have been had exchange rates remained stable from this past period until the three months ended December 31, 2025.

**Safe Harbor Statement**

This press release contains forward-looking statements. Forward-looking statements convey our current expectations or forecasts of future events. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to differ materially from the forward-looking statements that we make. Forward-looking statements typically are identified by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "project," "plan," "believe," "potential," "continue," "is/are likely to," or other similar expressions. Forward-looking statements that appear in a number of places in this press release include, but are not limited to, statements regarding the intent, belief or current expectations, regarding various matters, including, our target Leverage Ratio, the expected resolution of the issues with physicians, suppliers and information systems in Mexico, the results of the key initiatives we are implementing in Mexico, Colombia and Peru, the expected completion and opening of Centro Ambulatorio Trecca in 2028, the expected capacity and market of Centro Ambulatorio Trecca once built, the execution of our strategic plan, including the recovery of our growth levels and the roll-out of the AunaWay in Mexico, our planned investments in Mexico, revenue and Adjusted EBITDA guidance, our expectation for revenue and EBITDA growth in Mexico and the creation of further growth and sustainable value for all stakeholders. Any or all of our forward-looking statements in this press release may turn out to be inaccurate. Our actual results could differ materially from those contained in forward-looking statements due to a number of factors.

The forward-looking statements in this press release represent our expectations and forecasts as of the date of this press release. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release. For a discussion of the risks facing the Company which could affect whether these forward-looking statements are realized, see our Form 20-F filing with the U.S. Securities and Exchange Commission (the "SEC").

**Financial Guidance Disclaimer**

Auna's guidance is based on management's current performance outlook and expected macroeconomic and regulatory conditions in the three countries where the Company operates. Any changes in these conditions could have an impact on the guidance provided.

Auna's financial guidance reflects management's current assumptions regarding numerous evolving factors that are difficult to accurately predict, including those

discussed in the Risk Factors set forth in the Company's Form 20-F filed with the SEC. Reconciliations of forward-looking non-IFRS measures, specifically the 2026 Adjusted EBITDA guidance, to the relevant forward-looking IFRS measures are not being provided, as the Company does not currently have sufficient data to accurately estimate the variables and individual adjustments for such guidance and reconciliations. Due to this uncertainty, the Company cannot reconcile projected Adjusted EBITDA to projected net income without unreasonable effort. The financial guidance constitutes forward-looking statements. For more information, see the "Forward-Looking Statements" section in this release.

**IR Contact** 

Email: contact@aunainvestors.com

- Financial Tables Follow –

**Balance Sheet (1/2)**

*(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Dec-25<br> (USD)**  | **Dec-25** | **Dec-24** | **Δ Dec-25 vs Dec-24** |
| **Assets** |  |  |  |  |
| Current assets |  |  |  |  |
| Cash and cash equivalents | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;100 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;335 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;236 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;100 |
| Trade accounts receivable | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;310 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1043 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;962 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;81 |
| Other assets | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;77 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;259 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;253 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5 |
| Inventories | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;49 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;165 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;144 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21 |
| Derivative financial instruments | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(9) |
| Insurance contract assets | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13 |
| Other investments | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;30 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;100 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(70) |
| **Total current assets** | **548** | **1845** | **1704** | **141** |
| **Non-current assets** |  |  |  |  |
| Trade accounts receivable | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) |
| Other assets | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 |
| Investments in associates and joint venture | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;30 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 |
| Property furniture and equipment | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;680 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2287 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2280 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7 |
| Intangible assets | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;804 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2704 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2657 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;47 |
| Right-of-use assets | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;34 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;113 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;131 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(18) |
| Investment properties | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 |
| Derivative financial instruments | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;54 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;59 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) |
| Deferred tax assets | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;69 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;231 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;194 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;37 |
| Other investments | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 |
| **Total non-current assets** | **1622** | **5454** | **5377** | **77** |
| **Total assets** | **2170** | **7298** | **7081** | **217** |

---

**Balance Sheet (2/2)**

*(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Dec-25<br> (USD)**  | **Dec-25** | **Dec-24** | **Δ Dec-25 vs Dec-24** |
| **Liabilities** |  |  |  |  |
| **Current liabilities** |  |  |  |  |
| Loans and borrowings | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;94 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;316 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;654 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(338) |
| Lease liabilities | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;29 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;32 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) |
| Trade accounts payable | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;313 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1053 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;931 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;122 |
| Other accounts payable | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;67 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;225 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;290 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(64) |
| Provisions | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) |
| Derivative financial instruments | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8 |
| Insurance contract liabilities | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) |
| Deferred income | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) |
| **Total current liabilities** | **496** | **1667** | **1945** | **(278)** |
| **Non-current liabilities** |  |  |  |  |
| Loans and borrowings | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;956 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3216 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2966 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;251 |
| Lease liabilities | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;28 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;94 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;115 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(21) |
| Trade accounts payable | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) |
| Other accounts payable | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;66 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;222 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;73 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;149 |
| Derivative financial instruments | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;40 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13 |
| Deferred tax liabilities | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;87 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;291 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;328 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(37) |
| Deferred income | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) |
| **Total non-current liabilities** | **1149** | **3865** | **3513** | **352** |
| **Total liabilities** | **1645** | **5532** | **5458** | **74** |
| **Total equity** | **525** | **1766** | **1623** | **143** |
| **Total liabilities and equity** | **2170** | **7298** | **7081** | **217** |

---

**Income Statement** 

*(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)*

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **4Q'25<br> (USD)** | **4Q'25** | **FY 25** | | |
|  | **4Q'25<br> (USD)** | **4Q'25** | **FY 25** | **Δ 4Q'25 vs**<br>**4Q'24** | **Δ FY 25 vs**<br>**FY 24** |
| **Revenue** |  |  |  |  |  |
| Healthcare Services Mexico | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;77 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;258 | &nbsp;&nbsp;&nbsp;&nbsp;1039 | -4% | -13% |
| Healthcare Services Colombia | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;115 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;385 | &nbsp;&nbsp;&nbsp;&nbsp;1435 | 9% | -1% |
| &nbsp;&nbsp;&nbsp;*- Healthcare Services Colombia* | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;115 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;387 | &nbsp;&nbsp;&nbsp;&nbsp;1440 | 9% | 0% |
| &nbsp;&nbsp;&nbsp;*- Holding and eliminations* | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) |  |  |
| Healthcare Services Peru & Oncosalud Peru | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;145 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;489 | &nbsp;&nbsp;&nbsp;&nbsp;1912 | 11% | 9% |
| &nbsp;&nbsp;&nbsp;*- Healthcare Services Peru* | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;81 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;273 | &nbsp;&nbsp;&nbsp;&nbsp;1084 | 11% | 9% |
| &nbsp;&nbsp;&nbsp;*- Oncosalud Peru* | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;90 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;304 | &nbsp;&nbsp;&nbsp;&nbsp;1164 | 10% | 9% |
| &nbsp;&nbsp;&nbsp;*- Holding and eliminations* | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(26) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(87) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(337) | 10% | 6% |
| **Total Revenue** | **337** | **1133** | **4385** | **7%** | **0%** |
| Cost of sales and services | (209) | (704) | (2722) | 12% | 2% |
| **Gross profit** | **127** | **429** | **1664** | **-1%** | **-4%** |
| *Gross margin* |  | *37.8%* | *37.9%* | *-3.0 p.p.* | *-1.4 p.p.* |
| Selling expenses | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(16) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(54) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(221) | 28% | 12% |
| Administrative expenses | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(66) | &nbsp;&nbsp;&nbsp;&nbsp;(222) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(813) | 11% | 3% |
| (Loss) reversal for impairment of trade receivables | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(19) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(48) | 49% | 18% |
| Other income and expenses, net | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;43 | -9% | -50% |
| **Operating profit** | **43** | **144** | **625** | **-24%** | **-20%** |
| Finance income | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22 | -1% | -12% |
| Finance income from exchange difference | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;48 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;193 | -2.5x |  |
| Finance costs | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(87) | &nbsp;&nbsp;&nbsp;&nbsp;(292) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(651) | 1.1x | 10% |
| Finance costs from exchange difference | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- |  |  |
| **Net finance cost** | **(71)** | **(238)** | **(436)** | **53%** | **-28%** |
| Share of profit of equity accounted investees | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 | 2 | 10 | 2% | 18% |
| **Profit (loss) before tax** | **-27** | **(91)** | **199** | **-3.4x** | **0.1x** |
| Income tax expense (benefit) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(88) | -3.0x | 0.5x |
| **Net Income (Loss)** | **(19)** | **(64)** | **111** | **-3.7x** | **-0.1x** |
| **EBITDA** |  |  |  |  |  |
| Healthcare Services Mexico | 16 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;54 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;266 | -37% | -40% |
| Healthcare Services Colombia | 14 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;48 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;197 | -25% | -9% |
| Healthcare Services Peru & Oncosalud Peru | 26 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;88 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;397 | -5% | 9% |
| &nbsp;&nbsp;&nbsp;*- Healthcare Services Peru* | *7* | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;140 | *4%* | *4%* |
| &nbsp;&nbsp;&nbsp;*- Oncosalud Peru* | *19* | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;65 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;257 | *-8%* | *12%* |
| Holding and eliminations | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) |  |  |
| **Total EBITDA** | **60** | **203** | **858** | **-17%** | **-15%** |
| **Adjusted EBITDA** |  |  |  |  |  |
| Healthcare Services Mexico | 18 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;59 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;304 | -37% | -26% |
| Healthcare Services Colombia | 15 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;50 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;201 | -23% | -8% |
| Healthcare Services Peru & Oncosalud Peru | 33 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;109 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;423 | 14% | 14% |
| &nbsp;&nbsp;&nbsp;*- Healthcare Services Peru* | *8* | *29* | *148* | *21%* | *6%* |
| &nbsp;&nbsp;&nbsp;*- Oncosalud Peru* | *24* | *81* | *275* | *12%* | *19%* |
| Holding and eliminations | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(11) |  |  |
| **Total Adjusted EBITDA** | **66** | **220** | **917** | **-13%** | **-8%** |
| ***Adjusted EBITDA Margin*** |  | ***19.5%*** | ***20.9%*** | **-4.5 p.p.** | **-1.7 p.p.** |

---

**Statement of Cash Flows (1/2)**

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **FY 25<br> (USD)**  | **FY 25** | **FY 24** | **Δ FY 25 vs<br> FY 24**  |
| **Cash flows from operating activities** |  |  |  |  |
| (Loss) profit for the period | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;33 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;111 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;124 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(13) |
| **Adjustments for:** |  |  |  |  |
| Depreciation | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;34 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;115 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;115 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 |
| Depreciation of right-of-use assets | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;28 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;28 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 |
| Amortization | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;79 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;76 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3 |
| Other income for reversal of others accounts payable to former shareholders | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(47) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;47 |
| Change in fair value of investment property | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 |
| (Reversal) Impairment of inventories | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 |
| Equity-settled share-based payment transactions | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 |
| Gain (loss) on disposal of property furniture and equipment | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) |
| Loss on disposal of right-of-use assets net of leases | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) |
| Loss on disposal of intangibles | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) |
| Derecognition of other assets | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) |
| (Reversal) loss for impairment of trade receivables | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;48 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;41 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7 |
| Share of profit of equity-accounted investees | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(10) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(9) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) |
| Technical provisions and other provisions | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 |
| Finance income | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(64) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(215) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(25) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(190) |
| Finance costs | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;194 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;651 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;634 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18 |
| Tax expense | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;88 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;60 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;29 |
| **Net changes in assets and liabilities** |  |  |  |  |
| Trade accounts receivable and other assets | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(24) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(82) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(343) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;262 |
| Inventories | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(18) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(26) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8 |
| Trade accounts payable and other accounts payable | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;65 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;230 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(165) |
| Provisions and employee benefits | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 |
| Insurance contract liabilities | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(13) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(29) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15 |
| **Cash generated from operating activities** | **255** | **856** | **842** | **15** |
| Income tax paid | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(62) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(209) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(194) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(15) |
| Interest received | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6) |
| **Net cash from operating activities** | **197** | **663** | **668** | **(6)** |

---

**Statement of Cash Flows (2/2)**

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **FY 25<br> (USD)**  | **FY 25** | **FY 24** | **Δ FY 25 vs<br> FY 24**  |
| **Cash flows from investing activities** |  |  |  |  |
| Payment for accounts payables to former shareholder | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(21) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(30) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9 |
| Purchase of properties furniture and equipment | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(26) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(86) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(91) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5 |
| Purchase of intangibles | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(17) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(59) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(51) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(8) |
| Dividends from equity-accounted investees | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 |
| Purchase of other investments, net of sales | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;76 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(21) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;97 |
| Proceeds from sale of property furniture and equipment | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6 |
| Payment for contingent consideration | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(47) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;47 |
| **Net cash used in investing activities** | **(24)** | **(80)** | **(237)** | **157** |
| **Cash flows from financing activities** |  |  |  |  |
| Proceeds from issuance of common stock in initial public offering, net of issuance costs | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1268 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1268) |
| Proceeds from settlement of derivatives - interest rate swaps | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(23) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(21) |
| Payments of initial public offering costs | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(16) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16 |
| Proceeds from loans and borrowings | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1218 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4098 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1239 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2858 |
| Payment for loans and borrowings | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1196) | &nbsp;&nbsp;&nbsp;&nbsp;(4022) | &nbsp;&nbsp;&nbsp;&nbsp;(1126) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2897) |
| Payment for lease liabilities | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(13) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(44) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(46) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 |
| Penalty paid for debt prepayment | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) |
| Payment for costs of Extinguishment of debt | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(19) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(65) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(17) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(48) |
| Payment for derivatives premiums | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(23) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(51) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;28 |
| Interest paid | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(121) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(408) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(451) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;43 |
| Dividends paid | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 |
| Acquisition of non-controlling interest | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;(1218) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1218 |
| **Net cash used in financing activities** | **(145)** | **(487)** | **(418)** | **(69)** |
| Net (decrease) increase in cash and cash equivalents | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;28 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;95 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;82 |
| Cash and cash equivalents at January 1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;70 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;236 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;241 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) |
| Effect of movements in exchange rates on cash held | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(19) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23 |
| **Cash and cash equivalents at the end of the period** | **100** | **335** | **236** | **100** |

---

**Historical Financial Metrics** 

*(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)*

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **4Q'23** | **1Q'24** | **2Q'24** | **3Q'24** | **4Q'24** | **1Q'25** | **2Q'25** | **3Q'25** | **4Q'25** |
| **Revenue** |  |  |  |  |  |  |  |  |  |
| Oncosalud Peru | 244 | 253 | 269 | 273 | 276 | 281 | 286 | 294 | 304 |
| Healthcare Services Peru | 225 | 241 | 255 | 255 | 245 | 263 | 269 | 279 | 273 |
| Healthcare Services Colombia | 335 | 349 | 378 | 363 | 353 | 339 | 346 | 369 | 387 |
| Healthcare Services Mexico | 284 | 308 | 302 | 316 | 268 | 243 | 274 | 264 | 258 |
| Holding and eliminations | (67) | (76) | (83) | (80) | (79) | (84) | (81) | (88) | (89) |
| **Total revenue from contracts with customers** | **1021** | **1076** | **1120** | **1127** | **1063** | **1042** | **1094** | **1117** | **1133** |
| Cost of sales and services | (645) | (662) | (693) | (677) | (629) | (660) | (660) | (698) | (704) |
| **Gross profit** | **376** | **414** | **427** | **449** | **434** | **382** | **434** | **419** | **429** |
| Selling expenses | (42) | (53) | (48) | (55) | (42) | (54) | (54) | (59) | (54) |
| Administrative expenses | (193) | (191) | (202) | (195) | (201) | (182) | (208) | (200) | (222) |
| Impairment losses on trade receivables | (2) | 0 | (3) | (25) | (13) | (16) | (8) | (5) | (19) |
| Other expenses | (21) | 0 | 0 | 0 | (2) | 0 | 0 | 0 | 0 |
| Other income | 13 | 11 | 8 | 54 | 14 | 9 | 12 | 11 | 11 |
| **Operating profit** | **130** | **182** | **183** | **229** | **190** | **139** | **176** | **166** | **144** |
| Finance income | 6 | 6 | 7 | 6 | 7 | 6 | 5 | 4 | 6 |
| Finance income from exchange difference | 33 | 3 | 0 | 28 | (31) | 37 | 68 | 40 | 48 |
| Finance costs | (357) | (177) | (139) | (138) | (138) | (123) | (120) | (116) | (292) |
| Finance costs from exchange difference | 17 | 0 | (49) | 0 | 8 | 0 | 0 | 0 | 0 |
| **Net finance cost** | **(302)** | **(168)** | **(182)** | **(103)** | **(155)** | **(80)** | **(46)** | **(72)** | **(238)** |
| Share of profit of equity-accounted investees | 1 | 2 | 2 | 2 | 2 | 3 | 2 | 3 | 2 |
| **Profit (loss) before tax** | **(170)** | **16** | **3** | **127** | **37** | **62** | **132** | **97** | **(91)** |
| Income tax (expense) benefit | (50) | (25) | 5 | (27) | (13) | (24) | (48) | (44) | 27 |
| **Net Income** | **(219)** | **(8)** | **8** | **101** | **24** | **38** | **84** | **53** | **(64)** |
| **EBITDA** | **188** | **241** | **241** | **286** | **244** | **195** | **234** | **226** | **203** |
| **EBITDA Adjustments** |  |  |  |  |  |  |  |  |  |
| Net Income | (219) | (8) | 8 | 101 | 24 | 38 | 84 | 53 | (64) |
| Income tax expense | 50 | 25 | (5) | 27 | 13 | 24 | 48 | 44 | (27) |
| Net finance cost | 302 | 168 | 182 | 103 | 155 | 80 | 46 | 72 | 238 |
| Depreciation and amortization | 56 | 56 | 56 | 55 | 52 | 53 | 55 | 57 | 56 |
| &nbsp;&nbsp;&nbsp;*(a) Pre-operating expenses* | *0* | *0* | *2* | *0* | *0* | *0* | *0* | *(0)* | *0* |
| &nbsp;&nbsp;&nbsp;*(b) Business development expenses* | *0* | *0* | *1* | *(44)* | *3* | *24* | *4* | *4* | *10* |
| &nbsp;&nbsp;&nbsp;*(c) Change in fair value of earn-out liabilities* | *21* | *0* | *0* | *0* | *0* | *0* | *0* | *0* | *0* |
| &nbsp;&nbsp;&nbsp;*(d) Stock-based consideration* | *4* | *0* | *0* | *6* | *3* | *3* | *3* | *3* | *3* |
| &nbsp;&nbsp;&nbsp;*(e)Personnel non-recurring compensation* | *0* | *0* | *4* | *2* | *5* | *0* | *0* | *0* | *5* |
| &nbsp;&nbsp;&nbsp;*(f) Change in fair value of investment properties* | *0* | *0* | *0* | *0* | *0* | *0* | *0* | *0* | *0* |
| **Adjusted EBITDA** | **213** | **241** | **248** | **250** | **254** | **222** | **241** | **232** | **220** |

---

**Key Operating Metrics**

---

| | | | |
|:---|:---|:---|:---|
| | **FY 25** | **FY 24** | **Δ FY 25 vs<br> FY 24**  |
| <br>**Oncosalud Peru** |  |  |  |
| **Plan memberships <sup>(1) (2)</sup>** | **1424695** | **1365028** | **4%** |
| **Average monthly revenue per plan member <sup>(3)</sup>** | **S/ 61.12** | **S/ 58.92** | **3.7%** |
| **Preventive check-ups <sup>(4)</sup>** | **120875** | **106457** | **13.5%** |
| **Patients treated <sup>(5)</sup>** | **74097** | **58559** | **26.5%** |
| **Medical loss ratio <sup>(6)</sup>** | **54.2%** | **57.3%** | **-3.1 p.p** |
| **Healthcare Services** |  |  |  |
| **Total bed capacity <sup>(1)(7)</sup>** | **2224** | **2214** | **0.5%** |
| **Surgeries <sup>(8)</sup>** | **82579** | **88668** | **-6.9%** |
| **Emergency treatments <sup>(9)</sup>** | **358951** | **365942** | **-1.9%** |
| **Operating capacity utilization <sup>(10)</sup>** | **77.0%** | **81.6%** | **-4.6 p.p** |
| **Total capacity utilization <sup>(11)</sup>** | **64.1%** | **66.4%** | **-2.3 p.p** |

---

1) As of period end and as reported to the National Superintendence of Health Susalud. Includes Oncology plans and Health plans.

2) Includes active plan members and inactive members. Inactive members are defined as those plan members that have not paid monthly fees due for up to three months. As of December, 31, 2025, we had 1,325,062 active members and 99,633 inactive members.

3) Total revenue for the period corresponding to insurance revenue in the Oncosalud Peru segment divided by the average number of plan members during the period, divided by the number of months in the period.

4) Preventive check-ups consider Oncology check-ups at the Centro de Bienestar Ambulatorio – CBA (wellness center) in Lima, Peru. The number of Healthcare checkups is negligible.

5) Number of individual plan members receiving treatment for cancer during the period, which may include multiple instances of treatment per plan member.

6) MLR is calculated as (i) claims for medical treatment generated by our prepaid oncology and general healthcare plans plus (ii) technical reserves relating to plan members treated pursuant to such plans, whether at our facilities or third-party facilities, divided by revenue generated by our prepaid oncology and general healthcare plans.

7) Includes all beds within the Healthcare Network and excludes 109 Oncology beds.

8) Number of surgeries includes surgeries outpatient surgeries and cesarean sections

9) Emergency care includes the number of visits in the emergency room and may include several visits per patient.

10) Operating capacity utilization (Occupancy) is calculated as (i) (x) total number of days in which any of our beds had a hospitalized patient during the period divided by (y) total number of operating beds, times (ii) total number of days during the period.

11) Total capacity utilization (Occupancy) is calculated as (i) (x) total number of days in which any of our beds had a hospitalized patient during the period divided by (y) total number of beds, times (ii) total number of days during the period.

## Exhibit 99.2

**EXHIBIT 99.2**

Auna S.A. and Subsidiaries<br> Consolidated Financial Statements<br>**December 31, 2025**<br>

**Auna S.A. and Subsidiaries** 

Consolidated Financial Statements

**December 31, 2025**

---

| | |
|:---|:---|
| **Contents** | **Page** |
| Consolidated Statement of Financial Position | 1 |
| Consolidated Statement of Profit or Loss and Other Comprehensive Income | 2 |
| Consolidated Statement of Changes in Equity | 3 |
| Consolidated Statement of Cash Flows | 4 |
| Operating Segments | 5 - 9 |

---

---

| |
|:---|
| **Auna S.A. and Subsidiaries** |
| Consolidated Statement of Financial Position |
| As of December 31, 2025, 2024 and 2023 |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| *In thousands of soles* | **2025** | **2024** | **2023** | *In thousands of soles* | **2025** | **2024** | **2023** |
| **Assets** |  |  |  | **Liabilities** |  |  |  |
| **Current assets** |  |  |  | **Current liabilities** |  |  |  |
| Cash and cash equivalents | 335441 | 235745 | 241133 | Loans and borrowings | 316339 | 654233 | 385300 |
| Trade accounts receivable | 1042792 | 961886 | 860916 | Lease liabilities | 29282 | 32459 | 31867 |
| Other assets | 258511 | 253283 | 222728 | Trade accounts payable | 1053395 | 931265 | 749349 |
| Inventories | 164798 | 143764 | 130521 | Other accounts payable | 225465 | 289563 | 463600 |
| Derivative financial instruments |  | 8962 | 721 | Provisions | 10161 | 12246 | 19074 |
| Other investments | 30237 | 100228 | 93132 | Derivative financial instruments | 22903 | 15273 |  |
| Insurance contract assets | 12778 | - | - | Insurance contract liabilities | 9447 | 10098 | 39853 |
| **Total current assets** | **1844557** | **1703868** | **1549151** | Deferred income | 98 | 138 | 267 |
|  |  |  |  | **Total current liabilities** | **1667090** | **1945275** | **1689310** |
| **Non-current assets** |  |  |  |  |  |  |  |
| Trade accounts receivable | 486 | 571 | 420 | **Non-current liabilities** |  |  |  |
| Other assets | 26910 | 24433 | 21573 | Loans and borrowings | 3216171 | 2965541 | 3376282 |
| Investments in associates and joint venture | 29848 | 25405 | 20584 | Lease liabilities | 94237 | 115429 | 126178 |
| Property, furniture, and equipment | 2287002 | 2280123 | 2573140 | Trade accounts payable | 1450 | 2741 | 3906 |
| Intangible assets | 2704351 | 2656888 | 3129187 | Other accounts payable | 221940 | 73150 | 221132 |
| Right-of-use assets | 113116 | 131062 | 139386 | Derivative financial instruments | 39647 | 27097 |  |
| Investment properties | 6340 | 6058 | 6959 | Deferred tax liabilities<br> Deferred income | 291086<br> 87 | 328370<br> 177 | 495826<br> 352 |
| Derivative financial instruments | 54036 | 58510 | 81492 | Deferred tax liabilities<br> Deferred income | 291086<br> 87 | 328370<br> 177 | 495826<br> 352 |
| Deferred tax assets | 230716 | 193520 | 167371 | **Total non-current liabilities** | **3864618** | **3512505** | **4223676** |
| Other investments | 702 | 282 | 289 | **Total liabilities** | **5531708** | **5457780** | **5912986** |
| **Total non-current assets** | **5453507** | **5376852** | **6140401** | **Equity** |  |  |  |
|  |  |  |  | **Equity** |  |  |  |
|  |  |  |  | Share capital | 17389 | 17387 | 8820 |
|  |  |  |  | Share premium | 1209715 | 1208586 |  |
|  |  |  |  | Reserves | 566271 | 524776 | 1823364 |
|  |  |  |  | Retained losses | (192615) | (273533) | (366899) |
|  |  |  |  | **Equity attributable to the owner of the Company** | **1600760** | **1477216** | **1465285** |
|  |  |  |  | Non-controlling interest | 165596 | 145724 | 311281 |
|  |  |  |  | **Total equity** | **1766356** | **1622940** | **1776566** |
| **Total assets** | **7298064** | **7080720** | **7689552** | **Total liabilities and equity** | **7298064** | **7080720** | **7689552** |

---

---

| |
|:---|
| **Auna S.A. and Subsidiaries** |
| Consolidated Statement of Profit or Loss and Other Comprehensive Income |
| For the years ended December 31, 2025, 2024 and 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| *In thousands of soles* | **2025** | **2024** | **2023** |
| **Revenue** |  |  |  |
| Insurance revenue | 1131455 | 1052958 | 914182 |
| Healthcare services revenue | 2918881 | 3012454 | 2695860 |
| Sales of medicines | 334962 | 320700 | 265865 |
| **Total revenue from contracts with customers** | **4385298** | **4386112** | **3875907** |
| Cost of sales and services | (2721585) | (2660819) | (2440561) |
| **Gross profit** | **1663713** | **1725293** | **1435346** |
| Selling expenses | (220859) | (197475) | (193943) |
| Administrative expenses | (812672) | (788677) | (704565) |
| Loss for impairment of trade receivables | (48054) | (40855) | (5684) |
| Other expenses |  | (2112) | (20927) |
| Other income | 43164 | 87586 | 50113 |
| **Operating profit** | **625292** | **783760** | **560340** |
| Finance income | 21833 | 24810 | 17126 |
| Finance income from exchange difference | 193004 |  | 75852 |
| Finance costs | (651290) | (591884) | (783782) |
| Finance costs from exchange difference | - | (41709) | - |
| **Net finance cost** | **(436453)** | **(608783)** | **(690804)** |
| **Share of profit of equity-accounted investees** | **10414** | **8800** | **6290** |
| **Income (loss) before tax** | **199253** | **183777** | **(124174)** |
| Income tax expense | (88353) | (59819) | (90170) |
| **Profit (loss) for the year** | **110900** | **123958** | **(214344)** |
| **Other comprehensive income** |  |  |  |
| **Items that are or may be reclassified subsequently to profit or loss** |  |  |  |
| Cash flow hedges | (292) | 3768 | 13762 |
| Foreign operations – Foreign currency translation differences | 90704 | (409746) | 390180 |
| Remeasurements of defined benefit liability | (78) | 1523 | (2202) |
| Change in fair value of put liability |  |  | 40430 |
| Other investments at FVOCI – net change in fair value | (1147) | 1072 | 188 |
| Equity-accounted investees – share of OCI |  |  | (42) |
| Income tax | 248 | (1744) | (4305) |
| **Other comprehensive income (loss) for the year, <br> net of tax** | **89435** | **(405127)** | **438011** |
| **Total comprehensive income (loss) for the year** | **200335** | **(281169)** | **223667** |
| **Income (loss) attributable to:** |  |  |  |
| Owner of the Company | 97614 | 110271 | (253921) |
| Non-controlling interest | 13286 | 13687 | 39577 |
|  | **110900** | **123958** | **(214344)** |
| **Total comprehensive income (loss) attributable to:** |  |  |  |
| Owner of the Company | 180463 | (276855) | 84292 |
| Non-controlling interest | 19872 | (4314) | 139375 |
|  | **200335** | **(281169)** | **223667** |
| **Earnings (loss) per share** |  |  |  |
| Basic earnings per share | 1.32 | 1.64 | (5.78) |
| Diluted earnings per share | 1.32 | 1.63 | (5.78) |

---

---

| |
|:---|
| **Auna S.A. and Subsidiaries** |
| Consolidated Statement of Changes in Equity |
| For the years ended December 31, 2025, 2024 and 2023 |

---

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | | | | | **Equity attributable to the owner of the Company**  | **Equity attributable to the owner of the Company**  | **Equity attributable to the owner of the Company**  | **Equity attributable to the owner of the Company**  | **Equity attributable to the owner of the Company**  | **Equity attributable to the owner of the Company**  | | |
| *In thousands of soles* | **Share**<br> **capital** | **Share**<br> **premium** | **Other <br> capital <br> reserve** | **Translation reserve** | **Cost of <br> hedging <br> reserve** | **Hedging**<br> **reserve** | **Merger and other**<br> **reserves** | **Shared-<br> based <br> payment reserve** | **Retained**<br> **earnings**<br> **(losses)** | **Total** | **Non-<br> controlling interest** | **Total**<br> **equity** |
| **Balances as of January 1, 2023** | **236547** | **386045** | **56314** | **(190389)** | **(15133)** | **(16756)** | **699333** | **-** | **(90982)** | **1064979** | **493082** | **1558061** |
| Loss for the year |  |  |  |  |  |  |  |  | (253921) | (253921) | 39577 | (214344) |
| Other comprehensive income for the year | - | - | - | 302095 | 28839 | (23191) | 30470 | - | - | 338213 | 99798 | 438011 |
| **Total comprehensive income for the year** | **-** | **-** | **-** | **302095** | **28839** | **(23191)** | **30470** | **-** | **(253921)** | **84292** | **139375** | **223667** |
| Transfer to legal reserve |  |  | 23468 |  |  |  |  |  | (23468) |  |  |  |
| Changes of participation NCI in subsidiary |  |  |  | 28360 | (7284) | 10399 | 283892 |  |  | 315367 | (315367) |  |
| Contributions from non-controlling Shareholder |  |  |  |  |  |  | (1016) |  |  | (1016) | 1032 | 16 |
| Shareholder's downstream merger | (227727) | (386045) |  |  |  |  | 613963 |  | (2203) | (2012) |  | (2012) |
| Dividend distribution |  |  |  |  |  |  |  |  |  |  | (6841) | (6841) |
| Equity-settled share-based payment | - | - | - | - | - | - | - | - | 3675 | 3675 | - | 3675 |
| **Total transactions with the owners of the Company** | **(227727)** | **(386045)** | **23468** | **28360** | **(7284)** | **10399** | **896839** | **-** | **(21996)** | **316014** | **(321176)** | **(5162)** |
| **Balances as of December 31, 2023** | **8820** | **-** | **79782** | **140066** | **6422** | **(29548)** | **1626642** | **-** | **(366899)** | **1465285** | **311281** | **1776566** |
| **Balances as of January 1, 2024** | **8820** | **-** | **79782** | **140066** | **6422** | **(29548)** | **1626642** | **-** | **(366899)** | **1465285** | **311281** | **1776566** |
| Profit for the year |  |  |  |  |  |  |  |  | 110271 | 110271 | 13687 | 123958 |
| Other comprehensive loss the year | - | - | - | (391745) | 8970 | (6946) | 2595 | - | - | (387126) | (18001) | (405127) |
| **Total comprehensive loss for the year** | **-** | **-** | **-** | **(391745)** | **8970** | **(6946)** | **2595** | **-** | **110271** | **(276855)** | **(4314)** | **(281169)** |
| Issuance of common stock, net of issuance costs | 1112 | 1204913 |  |  |  |  |  |  |  | 1206025 |  | 1206025 |
| Transfer to legal reserve |  |  | 13230 |  |  |  |  |  | (13230) |  |  |  |
| Capitalization of merger reserve | 7453 |  |  |  |  |  | (7453) |  |  |  |  |  |
| Reclassification of shared-based payment reserve |  |  |  |  |  |  |  | 3675 | (3675) |  |  |  |
| Changes of participation NCI in subsidiary |  |  |  |  |  |  | 183 |  |  | 183 | (183) |  |
| Issuance of shares | 2 | 3673 |  |  |  |  |  | (3675) |  |  |  |  |
| Acquisition of non-controlling interest |  |  |  | 18909 |  |  | (1076628) |  |  | (1057719) | (159910) | (1217629) |
| Derecognition of put liability |  |  |  |  |  |  | 131152 |  |  | 131152 |  | 131152 |
| Dividend distribution |  |  |  |  |  |  |  |  |  |  | (1150) | (1150) |
| Equity-settled share-based payment | - | - | - | - | - | - | - | 9145 | - | 9145 | - | 9145 |
| **Total transactions with the owners of the Company** | **8567** | **1208586** | **13230** | **18909** | **-** | **-** | **(952746)** | **9145** | **(16905)** | **288786** | **(161243)** | **127543** |
| **Balances as of December 31, 2024** | **17387** | **1208586** | **93012** | **(232770)** | **15392** | **(36494)** | **676491** | **9145** | **(273533)** | **1477216** | **145724** | **1622940** |
| **Balances as of January 1, 2025** | **17387** | **1208586** | **93012** | **(232770)** | **15392** | **(36494)** | **676491** | **9145** | **(273533)** | **1477216** | **145724** | **1622940** |
| Profit for the year |  |  |  |  |  |  |  |  | 97614 | 97614 | 13286 | 110900 |
| Other comprehensive income (loss) for the year | - | - | - | 84118 | (36538) | 36494 | (1225) | - |  | 82849 | 6586 | 89435 |
| **Total comprehensive income (loss) for the year** | **-** | **-** |  | **84118** | **(36538)** | **36494** | **(1225)** |  | **97614** | **180463** | **19872** | **200335** |
| Issuance of shares | 2 | 1129 |  |  |  |  |  | (1131) |  |  |  |  |
| Equity transaction for mandatory purchase of NCI |  |  |  |  |  |  | (68111) |  |  | (68111) |  | (68111) |
| Transfer to legal reserve |  |  | 16696 |  |  |  |  |  | (16696) |  |  |  |
| Equity-settled share-based payment | - | - | - | - | - | - | - | 11192 | - | 11192 | - | 11192 |
| **Total transactions with the owners of the Company** | **2** | **1129** | **16696** | **-** | **-** | **-** | **(68111)** | **10061** | **(16696)** | **(56919)** | **-** | **(56919)** |
| **Balances as of December 31, 2025** | **17389** | **1209715** | **109708** | **(148652)** | **(21146)** | **-** | **607155** | **19206** | **(192615)** | **1600760** | **165596** | **1766356** |

---

---

| |
|:---|
| **Auna S.A. and Subsidiaries** |
| Consolidated Statement of Cash Flows |
| For the years ended December 31, 2025, 2024 and 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| *In thousands of soles* | **2025** | **2024** | **2023** |
| **Cash flows from operating activities** |  |  |  |
| Profit (loss) for the year | 110900 | 123958 | (214344) |
| **Adjustments for:** |  |  |  |
| Depreciation | 115417 | 115237 | 132442 |
| Depreciation of right-of-use assets | 28233 | 27636 | 26577 |
| Amortization | 78781 | 76273 | 76731 |
| Change in fair value of investment property | (106) | (161) | (116) |
| Impairment (reversal) of inventories | 668 | 419 | (1927) |
| Equity-settled share-based payment transactions | 11192 | 9145 | 3675 |
| Gain (loss) on disposal of property, furniture, and equipment | (512) | 4491 | (696) |
| Gain (loss) on disposal of right-of-use assets net of leases | (20) | 79 | 743 |
| Loss on disposal of intangibles | 147 | 1117 | 477 |
| Other expenses for derecognition of other assets |  | 2112 |  |
| Other expenses for changes in contingent consideration |  |  | 20927 |
| Other income for reversal of contingent consideration |  |  | (4095) |
| Other income for reversal of others accounts payable to former shareholders |  | (46613) |  |
| Loss for impairment of trade receivables | 48054 | 40855 | 5684 |
| Share of profit of equity-accounted investees | (10414) | (8800) | (6290) |
| Provisions | 1344 | 1001 | 1176 |
| Finance income | (214837) | (24810) | (92978) |
| Finance costs | 651290 | 633593 | 783782 |
| Income tax expense | 88353 | 59819 | 90170 |
| **Net changes in assets and liabilities** |  |  |  |
| Trade accounts receivable and other assets | (81630) | (343151) | (316000) |
| Inventories | (17849) | (25853) | (30107) |
| Trade accounts payable and other accounts payable | 64604 | 229751 | 183740 |
| Provisions and employee benefits | (3716) | (5718) | (4328) |
| Insurance contract liabilities | (13465) | (28602) | 25068 |
| **Cash generated from operating activities** | **856434** | **841778** | **680311** |
| Income tax paid | (209005) | (194322) | (114726) |
| Interest received | 15074 | 21042 | 16828 |
| **Net cash from operating activities** | **662503** | **668498** | **582413** |
| **Cash flows from investing activities** |  |  |  |
| Acquisition of subsidiary, net of cash acquired |  |  | (59994) |
| Payment for accounts payable to former shareholder | (21145) | (30011) | (1368) |
| Purchase of properties, furniture, and equipment | (86010) | (90857) | (116248) |
| Purchase of intangibles | (58671) | (50991) | (48917) |
| Dividends from equity-accounted investees | 3378 | 3311 | 1439 |
| Other assets (Trust funds) |  |  | 94539 |
| Purchase of other investments, net of sales | 75685 | (21312) | (22246) |
| Proceeds from sale of property, furniture, and equipment | 6508 | 213 | 4194 |
| Payment for contingent consideration |  | (47174) | (36143) |
| Proceeds from (payment in advance for) purchase of shares | - | - | 11592 |
| **Net cash used in investing activities** | **(80255)** | **(236821)** | **(173152)** |
| **Cash flows from financing activities** |  |  |  |
| Proceeds from issuance of common stock in initial public offering, net of issuance costs |  | 1267794 |  |
| Payments of initial public offering costs |  | (15908) |  |
| Proceeds from loans and borrowings | 4097522 | 1239486 | 4871380 |
| Payment for loans and borrowings | (4022294) | (1125622) | (4520827) |
| Payment for lease liabilities | (43851) | (45593) | (42530) |
| Penalty paid for debt prepayment | (81) |  | (53285) |
| Payment for derivatives premiums | (22804) | (50705) | (51141) |
| Payment for costs of extinguishment of debt | (64818) | (16607) |  |
| Interest paid | (408268) | (450982) | (566774) |
| Proceeds from settlement of derivatives - interest rate swaps | (22504) | (1202) |  |
| Dividends paid |  | (1150) | (6841) |
| Contributions from non-controlling shareholders |  |  | 16 |
| Acquisition of non-controlling interest | - | (1217629) | - |
| **Net cash used in from financing activities** | **(487098)** | **(418118)** | **(370002)** |
| Net increase in cash and cash equivalents | 95150 | 13559 | 39259 |
| Cash and cash equivalents at January 1 | 235745 | 241133 | 208694 |
| Effect of movements in exchange rates on cash held | 4546 | (18947) | (6820) |
| **Cash and cash equivalents at December 31** | **335441** | **235745** | **241133** |
| **Transactions not representing cash flows** |  |  |  |
| Assets acquired through finance lease and other financing | 14737 | 26826 | 17892 |
| Assets acquired from suppliers in installments | 18365 | 10060 | 16834 |

---

---

| |
|:---|
| **Auna S.A. and Subsidiaries** |
| Notes to the Consolidated Financial Statements |
| December 31, 2025, 2024 and 2023 |

---

**Operating Segments**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**A.** **Basis for segmentation** 

The Group has determined four reportable segments. These operating segments are components of a company about which separate financial information is available that is regularly evaluated by the Board of Directors (Chief operating decision maker) in deciding how to allocate resources and assess performance.

The following summary describes the operations of each reportable segment.

---

| | |
|:---|:---|
| **Reportable segments** | **Operations** |
| Oncosalud Peru | &nbsp;&nbsp;Including our prepaid oncologic healthcare plans and healthcare services related to the treatment of cancer. |
| Healthcare services in Peru | &nbsp;&nbsp;Corresponds to medical services within the network of clinics and health centers in Peru. |
| Healthcare services in Colombia | &nbsp;&nbsp;Corresponds to medical services within the network of clinics and health centers in Colombia. |
| Healthcare services in Mexico | &nbsp;&nbsp;Corresponds to medical services within the network of clinics and health centers, and the insurance business in Mexico. |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**B.** **Information about reportable segments** 

Information related to each reportable segment is set out below. Segment profit (loss) before tax is used to measure performance because the chief operating decision maker believes that this information is the most relevant for the Group.

---

| |
|:---|
| **Auna S.A. and Subsidiaries** |
| Notes to the Consolidated Financial Statements |
| December 31, 2025, 2024 and 2023 |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Reportable segments** | **Reportable segments** | **Reportable segments** | **Reportable segments** | **Reportable segments** | | |
| <br>*In thousands of soles* | **Oncosalud <br> Peru** | **Healthcare <br> services in Peru** | **Healthcare services in Colombia** | **Healthcare services in Mexico** | **Total reportable**<br> **segments** | <br>**Holding and eliminations** | <br>**Total** |
| **2025** |  |  |  |  |  |  |  |
| External revenues | 1125381 | 786227 | 1434924 | 1038766 | 4385298 |  | 4385298 |
| Inter-segment revenue (i) | 38868 | 298046 | 5180 | - | 342094 | (342094) | - |
| **Segment revenue** | **1164249** | **1084273** | **1440104** | **1038766** | **4727392** | **(342094)** | **4385298** |
| External cost of service | (316390) | (730670) | (1054171) | (620354) | (2721585) |  | (2721585) |
| Inter-segment cost of service (i) | (295276) | (35266) | - | - | (330542) | 330542 | - |
| **Segment cost of service** | **(611666)** | **(765936)** | **(1054171)** | **(620354)** | **(3052127)** | **330542** | **(2721585)** |
| **Gross profit** | **552583** | **318337** | **385933** | **418412** | **1675265** | **(11552)** | **1663713** |
| External selling expenses | (180342) | (22654) | (5373) | (13836) | (222205) | 1346 | (220859) |
| **Segment selling expenses** | **(180342)** | **(22654)** | **(5373)** | **(13836)** | **(222205)** | **1346** | **(220859)** |
| External administrative expenses | (75148) | (121765) | (201976) | (237401) | (636290) |  | (636290) |
| Inter-segment administrative expenses | (5061) | (7631) |  |  | (12692) | 12692 |  |
| Corporate expenses | (75936) | (64811) | (14389) | (12690) | (167826) | (8556) | (176382) |
| **Segment administrative expenses** | **(156145)** | **(194207)** | **(216365)** | **(250091)** | **(816808)** | **4136** | **(812672)** |
| **Impairment losses on trade receivables** | **(2563)** | **(16807)** | **(24918)** | **(4138)** | **(48426)** | **372** | **(48054)** |
| **Other expenses** | **(11156)** | **(1191)** | **-** | **-** | **(12347)** | **12347** | **-** |
| Other income | 2789 | 6978 | 8940 | 29901 | 48608 | (5444) | 43164 |
| Inter-segment other income | 12797 | 966 | - | - | 13763 | (13763) | - |
| **Other income** | **15586** | **7944** | **8940** | **29901** | **62371** | **(19207)** | **43164** |
| **Segment operating profit (loss)** | **217963** | **91422** | **148217** | **180248** | **637850** | **(12558)** | **625292** |
| Share of profit of equity accounted investees, net of taxes | 3278 |  | 7136 |  | 10414 |  | 10414 |
| Exchange difference, net | 1996 | 4460 | 73491 | 16090 | 96037 | 96967 | 193004 |
| Interest expense, net | (17151) | (37995) | (95064) | (245843) | (396053) | (233404) | (629457) |
| **Segment profit (loss) before tax** | **206086** | **57887** | **133780** | **(49505)** | **348248** | **(148995)** | **199253** |
| **Other disclosures** |  |  |  |  |  |  |  |
| Depreciation and amortization | (35728) | (48537) | (41242) | (86224) | (211731) | (10700) | (222431) |
| Capital expenditure | (22793) | (33731) | (23004) | (50344) | (129872) | (11181) | (141053) |
| **Segment assets** | **2408375** | **1032322** | **2464878** | **3144939** | **9050514** | **(1752450)** | **7298064** |
| **Segment liabilities** | **1113312** | **618896** | **1361484** | **1959986** | **5053678** | **478030** | **5531708** |

---

---

| |
|:---|
| **Auna S.A. and Subsidiaries** |
| Notes to the Consolidated Financial Statements |
| December 31, 2025, 2024 and 2023 |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Reportable segments** | **Reportable segments** | **Reportable segments** | **Reportable segments** | **Reportable segments** | | |
| <br>*In thousands of soles* | **Oncosalud <br> Peru** | **Healthcare <br> services in Peru** | **Healthcare services in Colombia** | **Healthcare services in Mexico** | **Total reportable**<br> **segments** | <br>**Holding and eliminations** | <br>**Total** |
| **2024** |  |  |  |  |  |  |  |
| External revenues | 1030432 | 718051 | 1443032 | 1194597 | 4386112 |  | 4386112 |
| Inter-segment revenue (i) | 40188 | 277701 | - | - | 317889 | (317889) | - |
| **Segment revenue** | **1070620** | **995752** | **1443032** | **1194597** | **4704001** | **(317889)** | **4386112** |
| External cost of service | (307047) | (671370) | (1040646) | (641756) | (2660819) |  | (2660819) |
| Inter-segment cost of service (i) | (279344) | (36596) | - | - | (315940) | 315940 | - |
| **Segment cost of service** | **(586391)** | **(707966)** | **(1040646)** | **(641756)** | **(2976759)** | **315940** | **(2660819)** |
| **Gross profit** | **484229** | **287786** | **402386** | **552841** | **1727242** | **(1949)** | **1725293** |
| External selling expenses | (159619) | (19552) | (5689) | (11948) | (196808) | (667) | (197475) |
| **Segment selling expenses** | **(159619)** | **(19552)** | **(5689)** | **(11948)** | **(196808)** | **(667)** | **(197475)** |
| External administrative expenses | (78596) | (107736) | (197887) | (249202) | (633421) |  | (633421) |
| Inter-segment administrative expenses | (369) | (5593) |  |  | (5962) | 5962 |  |
| Corporate expenses | (64885) | (63407) | (11542) | (6567) | (146401) | (8855) | (155256) |
| **Segment administrative expenses** | **(143850)** | **(176736)** | **(209429)** | **(255769)** | **(785784)** | **(2893)** | **(788677)** |
| **Impairment losses on trade receivables** | **(511)** | **(7914)** | **(28397)** | **(3987)** | **(40809)** | **(46)** | **(40855)** |
| **Other expenses** | **-** | **-** | **-** | **-** | **-** | **(2112)** | **(2112)** |
| Other income | 3196 | 7386 | 9438 | 68818 | 88838 | (1252) | 87586 |
| Inter-segment other income | 10859 | 948 | - | - | 11807 | (11807) | - |
| **Other income** | **14055** | **8334** | **9438** | **68818** | **100645** | **(13059)** | **87586** |
| **Segment operating profit (loss)** | **194304** | **91918** | **168309** | **349955** | **804486** | **(20726)** | **783760** |
| Share of profit of equity accounted investees, net of taxes | 3305 |  | 5495 |  | 8800 |  | 8800 |
| Exchange difference, net | (1710) | (1189) | (67555) | (20823) | (91277) | 49568 | (41709) |
| Interest expense, net | (30833) | (46346) | (108301) | (264340) | (449820) | (117254) | (567074) |
| **Segment profit (loss) before tax** | **165066** | **44383** | **(2052)** | **64792** | **272189** | **(88412)** | **183777** |
| **Other disclosures** |  |  |  |  |  |  |  |
| Depreciation and amortization | (32651) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(42818) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(42404) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(92070) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(209943) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(9203) | &nbsp;&nbsp;&nbsp;&nbsp;(219146) |
| Capital expenditure | (31974) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(45180) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(43614) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(36436) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(157204) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(21530) | (178734) |
| **Segment assets** | **2260833** | **1034399** | **2299375** | **3079407** | **8674014** | **(1593294)** | **7080720** |
| **Segment liabilities** | **1105230** | **663499** | **1359899** | **1881392** | **5010020** | **447760** | **5457780** |

---

---

| |
|:---|
| **Auna S.A. and Subsidiaries** |
| Notes to the Consolidated Financial Statements |
| December 31, 2025, 2024 and 2023 |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Reportable segments** | **Reportable segments** | **Reportable segments** | **Reportable segments** | **Reportable segments** | | |
| <br>*In thousands of soles* | **Oncosalud <br> Peru** | **Healthcare <br> services in Peru** | **Healthcare services in Colombia** | **Healthcare services in Mexico** | **Total reportable**<br> **segments** | <br>**Holding and eliminations** | <br>**Total** |
| **2023** |  |  |  |  |  |  |  |
| External revenues | 895507 | 657923 | 1192089 | 1130388 | 3875907 |  | 3875907 |
| Inter-segment revenue (i) | 36173 | 225966 | - | - | 262139 | (262139) | - |
| **Segment revenue** | **931680** | **883889** | **1192089** | **1130388** | **4138046** | **(262139)** | **3875907** |
| External cost of service | (277611) | (645375) | (853887) | (663688) | (2440561) |  | (2440561) |
| Inter-segment cost of service (i) | (225196) | (34297) | - | - | (259493) | 259493 | - |
| **Segment cost of service** | **(502807)** | **(679672)** | **(853887)** | **(663688)** | **(2700054)** | **259493** | **(2440561)** |
| **Gross profit** | **428873** | **204217** | **338202** | **466700** | **1437992** | **(2646)** | **1435346** |
| External selling expenses | (163299) | (18065) | (6313) | (5518) | (193195) | (748) | (193943) |
| **Segment selling expenses** | **(163299)** | **(18065)** | **(6313)** | **(5518)** | **(193195)** | **(748)** | **(193943)** |
| External administrative expenses | (72532) | (94553) | (176915) | (211816) | (555816) |  | (555816) |
| Inter-segment administrative expenses | (908) | (4658) |  |  | (5566) | 5566 |  |
| Corporate expenses | (63867) | (60072) | (11810) | (8772) | (144521) | (4228) | (148749) |
| **Segment administrative expenses** | **(137307)** | **(159283)** | **(188725)** | **(220588)** | **(705903)** | **1338** | **(704565)** |
| **Impairment losses on trade receivables** | **(355)** | **142** | **(6352)** | **1097** | **(5468)** | **(216)** | **(5684)** |
| **Other expenses** | **(4479)** | - | **(20302)** | - | **(24781)** | **3854** | **(20927)** |
| Other income | 1388 | 8384 | 16223 | 26157 | 52152 | (2039) | 50113 |
| Inter-segment other income | 11001 | 966 | - | - | 11967 | (11967) | - |
| **Other income** | **12389** | **9350** | **16223** | **26157** | **64119** | **(14006)** | **50113** |
| **Segment operating profit (loss)** | **135822** | **36361** | **132733** | **267848** | **572764** | **(12424)** | **560340** |
| Share of profit of equity accounted investees, net of taxes | 2227 |  | 4063 |  | 6290 |  | 6290 |
| Exchange difference, net | (5741) | (1783) | 119884 | 74020 | 186380 | (110528) | 75852 |
| Interest expense, net | (24909) | (45770) | (109508) | (385597) | (565784) | (200872) | (766656) |
| **Segment profit (loss) before tax** | **107399** | **(11192)** | **147172** | **(43729)** | **199650** | **(323824)** | **(124174)** |
| **Other disclosures** |  |  |  |  |  |  |  |
| Depreciation and amortization | (31968) | (38997) | (40226) | (115650) | (226841) | (8909) | (235750) |
| Capital expenditure | (26385) | (27256) | (81965) | (49023) | (184629) | (15262) | (199891) |
| **Segment assets** | **2146867** | **889286** | **2435123** | **3763000** | **9234276** | **(1544724)** | **7689552** |
| **Segment liabilities** | **1101354** | **565754** | **1514739** | **2343238** | **5525085** | **387901** | **5912986** |

---

---

| |
|:---|
| **Auna S.A. and Subsidiaries** |
| Notes to the Consolidated Financial Statements |
| December 31, 2025, 2024 and 2023 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Inter-segment cost of service (claims expense) from the Oncosalud Peru segment and intersegment revenue from our Healthcare Services
in Peru segment are presented on a gross basis by adding the corresponding profit margin markup by our Healthcare Services in Peru segment
and vice versa. Likewise, our Oncosalud Peru segment consolidates Oncocenter Perú S.A.C., a subsidiary providing healthcare services
related to the exclusive treatment of cancer. In the separate financial statements of Oncocenter Perú S.A.C., the revenue mainly
consists of the insurance claims expense recorded as cost of sales in the separate financial statements of Oncosalud S.A.C., our insurance
subsidiary that is also consolidated in Oncosalud Peru segment. In the segment consolidation process, the related revenues from such healthcare
services are eliminated with the corresponding claims expense of our insurance subsidiary Oncosalud S.A.C., while the external cost (third
parties) of services incurred by Oncocenter Perú S.A.C. remains.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**C.** **Geographic information** 

The geographic information analyzes the Group's revenue and non-current assets by the country where it operates. In presenting the geographic information, segment revenue has been based on the geographic location of customers and segment assets were based on the geographic location of the assets.

---

| | | | |
|:---|:---|:---|:---|
| *In thousands of soles* | **2025** | **2024** | **2023** |
| **Revenue** |  |  |  |
| Peru | 1911608 | 1748483 | 1553430 |
| Colombia | 1434924 | 1443032 | 1192089 |
| México | 1038766 | 1194597 | 1130388 |
|  | **4385298** | **4386112** | **3875907** |
| **Non-current assets (\*)** |  |  |  |
| Peru | 909284 | 908301 | 871520 |
| Colombia | 1478338 | 1432141 | 1601604 |
| México | 2781133 | 2784380 | 3418414 |
|  | **5168755** | **5124822** | **5891538** |

---

*(\*) Non-current assets exclude deferred tax assets and derivatives.* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**D.** **Major customer** 

None of the revenue derives from transactions carried out with a single customer or counterparty which is equal to or greater than 10 percent or more of the total revenue of the Group for the years ended December 31, 2025, 2024 and 2023